

GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 13, 2003, 15:31:05 ; Search time 10.4014 Seconds
(without alignments)
596,865 Million cell updates/sec

Title: US-09-728-911-36

Perfect score: 1129
Sequence: 1 SDAHGTELPSPSPVWFEEAF.....ASRSNKGMSKEECISLTRQ 211

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 262574 seqs, 29422922 residues

T number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

Issued Patents AA:*
1: /cgn2_6/prodata/1/1aa/5A.COMB.pep:*
2: /cgn2_6/prodata/1/1aa/5B.COMB.pep:*
3: /cgn2_6/prodata/1/1aa/6A.COMB.pep:*
4: /cgn2_6/prodata/1/1aa/6B.COMB.pep:*
5: /cgn2_6/prodata/1/1aa/PCUTS.COMB.pep:*
6: /cgn2_6/prodata/1/1aa/backfile1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1129	100.0	578	1	US-08-424-788-5
2	1129	100.0	578	1	US-08-110-683-2
3	1129	100.0	578	2	US-08-683-743-2
4	1129	100.0	578	2	US-08-477-166-2
5	1129	100.0	578	2	US-08-472-097-2
6	1129	100.0	578	4	US-09-439-672-2
7	1129	100.0	578	5	PCT-US93-11638-2
8	1115	98.8	557	1	US-08-424-788-6
9	602	53.3	559	1	US-08-424-788-3
10	602	53.3	575	1	US-08-424-788-2
11	602	53.3	575	1	US-08-110-683-4
12	602	53.3	575	2	US-08-477-166-4
13	602	53.3	575	2	US-08-472-097-4
14	602	53.3	575	2	US-08-472-097-4
15	602	53.3	575	5	PCT-US93-11638-4
16	602	53.3	575	5	PCT-US93-11638-4
17	143	12.7	221	2	US-08-943-087-50
18	143	12.7	553	2	US-08-943-087-14
19	143	12.7	553	2	US-08-943-087-16
20	143	12.7	553	2	US-08-943-087-18
21	143	12.7	553	2	US-08-943-087-20
22	143	12.7	553	2	US-08-943-087-22
23	143	12.7	553	2	US-08-943-087-24
24	143	12.7	553	2	US-08-943-087-26
25	143	12.7	553	2	US-08-943-087-28
26	143	12.7	553	2	US-08-943-087-30
27	143	12.7	553	2	US-08-943-087-32

28	143	12.7	553	2	US-08-943-087-34	Sequence 34, Appl
29	143	12.7	553	2	US-08-943-087-36	Sequence 36, Appl
30	143	12.7	553	2	US-08-943-087-38	Sequence 38, Appl
31	143	12.7	553	2	US-08-943-087-40	Sequence 40, Appl
32	143	12.7	553	2	US-08-943-087-42	Sequence 42, Appl
33	143	12.7	553	2	US-08-943-087-44	Sequence 44, Appl
34	143	12.7	553	2	US-08-943-087-46	Sequence 46, Appl
35	143	12.7	553	2	US-08-943-087-48	Sequence 48, Appl
36	142	12.6	221	2	US-08-943-087-54	Sequence 54, Appl
37	142	12.6	221	2	US-08-943-087-56	Sequence 56, Appl
38	140	12.4	221	2	US-08-943-087-52	Sequence 52, Appl
39	140	12.4	221	2	US-08-943-087-50	Sequence 50, Appl
40	137	12.1	221	2	US-08-943-087-60	Sequence 60, Appl
41	119	10.5	574	2	US-08-908-713-2	Sequence 2, Appl1
42	107.5	9.5	325	2	US-08-683-743-4	Sequence 4, Appl1
43	103.5	9.2	224	4	US-08-871-5728-13	Sequence 13, Appl1
44	93.5	8.3	233	4	US-08-871-5728-8	Sequence 8, Appl1
45	88	7.8	337	4	US-08-871-5728-1	Sequence 1, Appl1

ALIGNMENTS

RESULT 1

US-08-424-788-5
Sequence 5, Application US/08424788
Patent No. 5716804

GENERAL INFORMATION:

APPLICANT: Moore, Kevin W.

APPLICANT: Wei, Sherry

TITLE OF INVENTION: MAMMALIAN INTERLEUKIN-10 (IL-10)

TITLE OF INVENTION: SUPER-ACTIVATING RECEPTORS; AND VARIANTS

NUMBER OF SEQUENCES: 16

CORRESPONDENCE ADDRESS:

ADDRESS: DNAX Research Institute

STREET: 901 California Avenue

CITY: Palo Alto

STATE: California

COUNTRY: USA

ZIP: 94304-1104

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/424,788

FILING DATE: 19-APR-1995

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Ching, Edwin P.

REGISTRATION NUMBER: 34,090

REFERENCE/DOCKET NUMBER: DX0501

TELECOMMUNICATION INFORMATION:

TELEPHONE: 415-852-9196

TELEFAX: 415-496-1200

INFORMATION FOR SEQ ID NO: 5:

SEQUENCE CHARACTERISTICS:

LENGTH: 578 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

US-08-424-788-5

Query Match 100.0%; Score 1129; DB 1; Length 578;
Best Local Similarity 100.0%; Pred. No. 2.5e-121;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SDAHGTELPSPSPVWFEEAFHHIHWPIPNQSSCTCYVALRYGIESNNSISNCSQT 60
Db 19 SDAHGTELPSPSPVWFEEAFHHIHWPIPNQSSCTCYVALRYGIESNNSISNCSQT 78

QY 61 LSYDLTAVTLDLYHSNGYRVARVADGSRHSNWTVTNTRFSVDVTLTVGSVNLEIHNGF 120
DB 79 LSYDLTAVTLDLYHSNGYRVARVADGSRHSNWTVTNTRFSVDVTLTVGSVNLEIHNGF 138
QY 121 ILGKIQLPRPKMAPANDYVESIFSHFREYETAIRKVPNGFTFTHKKVKHENFSLTSGEV 180
DB 139 ILGKIQLPRPKMAPANDYVESIFSHFREYETAIRKVPNGFTFTHKKVKHENFSLTSGEV 198
QY 181 GFQVQVPSVASRSNKGMSKEECISLTRQ 211
DB 199 GFQVQVPSVASRSNKGMSKEECISLTRQ 229

RESULT 2

US-08-110-683-2
; Sequence 2, Application US/08110683
; Patent No. 5789192
; GENERAL INFORMATION:
; APPLICANT: Moore, Kevin W.
; APPLICANT: Liu, Ying
; APPLICANT: Ho, Alice Suk-Yue
; APPLICANT: Hsu, Di-Hwei
; APPLICANT: Bazan, J. Fernando
; APPLICANT: Tan, Jimmy C.
; APPLICANT: Chou, Chuan-Chu
; TITLE OF INVENTION: Mammalian Receptors for Interleukin-10
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DNAX Research Institute
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/110.683
; FILING DATE: 23-AUG-1993
; CLASSIFICATION: 436
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/011.066
; FILING DATE: 29-JAN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Ching, Edwin P.
; REGISTRATION NUMBER: 34,090
; REFERENCE/DOCKET NUMBER: DX0335K1
; TELEPHONE: 415-852-9196
; TELEFAX: 415-496-1200
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 578 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-110-683-2

Query Match 100.0%; Score 1129; DB 1; Length 578;
Best Local Similarity 100.0%; Pred. No. 2.5e-121;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SDAHGTLPSPSPVWFEEFFHHILHWTPIPNQSESTCYEVALLRGYIESWNISNCSQT 60
DB 19 SDAHGTLPSPSPVWFEEFFHHILHWTPIPNQSESTCYEVALLRGYIESWNISNCSQT 78
QY 61 LSYDLTAVTLDLYHSNGYRVARVADGSRHSNWTVTNTRFSVDVTLTVGSVNLEIHNGF 120
DB 79 LSYDLTAVTLDLYHSNGYRVARVADGSRHSNWTVTNTRFSVDVTLTVGSVNLEIHNGF 138

QY 121 ILGKIQLPRPKMAPANDYVESIFSHFREYETAIRKVPNGFTFTHKKVKHENFSLTSGEV 180
DB 139 ILGKIQLPRPKMAPANDYVESIFSHFREYETAIRKVPNGFTFTHKKVKHENFSLTSGEV 198
QY 181 GFQVQVPSVASRSNKGMSKEECISLTRQ 211
DB 199 GFQVQVPSVASRSNKGMSKEECISLTRQ 229

RESULT 3

US-08-683-743-2
; Sequence 2, Application US/08683743
; Patent No. 5843657
; GENERAL INFORMATION:
; APPLICANT: Pestka, Sidney
; APPLICANT: Kotenko, Serguei
; TITLE OF INVENTION: CYTOKINE RECEPTOR SIGNAL TRANSDUCTION
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: David A. Jackson, Esq.
; STREET: 411 Hackensack Ave, Continental Plaza, 4th
; CITY: Hackensack
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/683.743
; FILING DATE: 17-JUL-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Jackson Esq., David A.
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 601-1-050
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-487-5800
; TELEFAX: 201-343-1684
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 578 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; FRAGMENT TYPE:
US-08-683-743-2

Query Match 100.0%; Score 1129; DB 2; Length 578;
Best Local Similarity 100.0%; Pred. No. 2.5e-121;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SDAHGTLPSPSPVWFEEFFHHILHWTPIPNQSESTCYEVALLRGYIESWNISNCSQT 60
DB 19 SDAHGTLPSPSPVWFEEFFHHILHWTPIPNQSESTCYEVALLRGYIESWNISNCSQT 78
QY 61 LSYDLTAVTLDLYHSNGYRVARVADGSRHSNWTVTNTRFSVDVTLTVGSVNLEIHNGF 120
DB 79 LSYDLTAVTLDLYHSNGYRVARVADGSRHSNWTVTNTRFSVDVTLTVGSVNLEIHNGF 138
QY 121 ILGKIQLPRPKMAPANDYVESIFSHFREYETAIRKVPNGFTFTHKKVKHENFSLTSGEV 180
DB 139 ILGKIQLPRPKMAPANDYVESIFSHFREYETAIRKVPNGFTFTHKKVKHENFSLTSGEV 198
QY 181 GFQVQVPSVASRSNKGMSKEECISLTRQ 211

Db 199 GEFCTOVKPSVASRSNKGMSKECISLTRQ 229

RESULT 4

US-08-477-166-2
; Sequence 2, Application US/08477166
; Patent No. 5863796
; GENERAL INFORMATION:
; APPLICANT: Moore, Kevin W.
; APPLICANT: Liu, Ying
; APPLICANT: Ho, Alice Suk-Yue
; APPLICANT: Hsu, Di-Hwei
; APPLICANT: Bazan, J. Fernando
; APPLICANT: Tan, Jimmy C.
; APPLICANT: Chou, Chuan-Chu
; TITLE OF INVENTION: Mammalian Receptors for Interleukin-10
; TITLE OF INVENTION: (IL-10)
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DNAX Research Institute
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/477.166
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/110,683
; FILING DATE: 23-AUG-1993
; APPLICATION NUMBER: US 08/011,066
; FILING DATE: 29-JAN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Ching, Edwin P.
; REGISTRATION NUMBER: 34,090
; REFERENCE/DOCKET NUMBER: DX0335K1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-852-9196
; TELEFAX: 415-496-1200
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 578 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-477-166-2

Query Match 100.0%; Score 1129; DB 2; Length 578;
Best Local Similarity 100.0%; Pred. No. 2.5e-121;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SDHAGTELPSPSVWFEEAFPHHILHWTPINPOSESTCYEVALRYGIESMNSISNSCOT 60
DB 19 SDHAGTELPSPSVWFEEAFPHHILHWTPINPOSESTCYEVALRYGIESMNSISNSCOT 78
QY 61 LSYDLTAVTLDLYHNGYRARVAVDGSRHSNMTVTNTRFSVDEVTLTVGSVNLINHG 120
DB 79 LSYDLTAVTLDLYHNGYRARVAVDGSRHSNMTVTNTRFSVDEVTLTVGSVNLINHG 138
QY 121 ILGKIQLPRPKAPANDTYESI FSHFREYEIAIRKVPGNFTTHKKVGHENFSLTSGEV 180
DB 139 ILGKIQLPRPKAPANDTYESI FSHFREYEIAIRKVPGNFTTHKKVGHENFSLTSGEV 198
QY 181 GEFCTOVKPSVASRSNKGMSKECISLTRQ 211
DB 199 GEFCTOVKPSVASRSNKGMSKECISLTRQ 229

RESULT 5

US-08-472-097-2
; Sequence 2, Application US/08472097
; Patent No. 5868828
; GENERAL INFORMATION:
; APPLICANT: Moore, Kevin W.
; APPLICANT: Liu, Ying
; APPLICANT: Ho, Alice Suk-Yue
; APPLICANT: Hsu, Di-Hwei
; APPLICANT: Bazan, J. Fernando
; APPLICANT: Tan, Jimmy C.
; APPLICANT: Chou, Chuan-Chu
; TITLE OF INVENTION: Mammalian Receptors for Interleukin-10
; TITLE OF INVENTION: (IL-10)
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DNAX Research Institute
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/472.097
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/110,683
; FILING DATE: 23-AUG-1993
; APPLICATION NUMBER: US 08/011,066
; FILING DATE: 29-JAN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Ching, Edwin P.
; REGISTRATION NUMBER: 34,090
; REFERENCE/DOCKET NUMBER: DX0335K1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-852-9196
; TELEFAX: 415-496-1200
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 578 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-472-097-2

Query Match 100.0%; Score 1129; DB 2; Length 578;
Best Local Similarity 100.0%; Pred. No. 2.5e-121;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SDHAGTELPSPSVWFEEAFPHHILHWTPINPOSESTCYEVALRYGIESMNSISNSCOT 60
DB 19 SDHAGTELPSPSVWFEEAFPHHILHWTPINPOSESTCYEVALRYGIESMNSISNSCOT 78
QY 61 LSYDLTAVTLDLYHNGYRARVAVDGSRHSNMTVTNTRFSVDEVTLTVGSVNLINHG 120
DB 79 LSYDLTAVTLDLYHNGYRARVAVDGSRHSNMTVTNTRFSVDEVTLTVGSVNLINHG 138
QY 121 ILGKIQLPRPKAPANDTYESI FSHFREYEIAIRKVPGNFTTHKKVGHENFSLTSGEV 180
DB 139 ILGKIQLPRPKAPANDTYESI FSHFREYEIAIRKVPGNFTTHKKVGHENFSLTSGEV 198
QY 181 GEFCTOVKPSVASRSNKGMSKECISLTRQ 211
DB 199 GEFCTOVKPSVASRSNKGMSKECISLTRQ 229

RESULT 6

US-09-439-672-2
; Sequence 2, Application US/09439672
; Patent No. 6423500
; GENERAL INFORMATION:
; APPLICANT: Moore, Kevin W.
; APPLICANT: Liu, Ying
; APPLICANT: Ho, Alice Suk-Yue
; APPLICANT: Hsu, Di-Hwei
; APPLICANT: Bazan, J. Fernando
; APPLICANT: Tan, Jimmy C.
; APPLICANT: Chou, Chuan-Chu
; TITLE OF INVENTION: Mammalian Receptors for Interleukin-10
; TITLE OF INVENTION: (IL-10)
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DNAX Research Institute
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/439,672
; FILING DATE:
; CLASSIFICATION:
; Prior Application Data:
; APPLICATION NUMBER: 08/110,683
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Ching, Edwin P.
; REGISTRATION NUMBER: 34,090
; REFERENCE/DOCKET NUMBER: DX0335K1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-852-9196
; TELEFAX: 415-496-1200
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 578 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein

US-09-439-672-2

Query Match 100.0%; Score 1129; DB 4; Length 578;
Best Local Similarity 100.0%; Pred. No. 2.5e-121;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SDAHGTELPSPSPVWFEEFFHHILHWTPIPNQSESTCYEVALRYGIESWNSISNCSQT 60
DB 19 SDAHGTELPSPSPVWFEEFFHHILHWTPIPNQSESTCYEVALRYGIESWNSISNCSQT 78
QY 61 LSYDLTAVTLDLYHSGNGYRVARVDGSRHSNWTVTNTRFSVDEVTLTVGSVNLEIHNGF 120
DB 79 LSYDLTAVTLDLYHSGNGYRVARVDGSRHSNWTVTNTRFSVDEVTLTVGSVNLEIHNGF 138
QY 121 ILGKIQLPRPKMAPANDTYESIFSHFREYEAIRKVPNGFTFTHKKVKHENFSLTSGEV 180
DB 139 ILGKIQLPRPKMAPANDTYESIFSHFREYEAIRKVPNGFTFTHKKVKHENFSLTSGEV 198
QY 181 GFECVQKPSVASRSNKGWSKEECISLTRQ 211
DB 199 GFECVQKPSVASRSNKGWSKEECISLTRQ 229

RESULT 7

PCT-US93-11638-2

; Sequence 2, Application PC/TUS9311638
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Mammalian Receptors For Interleukin-10 (IL-10)
; NUMBER OF SEQUENCES: 12
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.8
; SOFTWARE: Microsoft Word 5.1a
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/11638
; FILING DATE:
; Prior Application Data:
; APPLICATION NUMBER: US 08/110,683
; FILING DATE: 23-AUG-1993
; Prior Application Data:
; APPLICATION NUMBER: US 08/011,066
; FILING DATE: 29-JAN-1993
; Prior Application Data:
; APPLICATION NUMBER: US 07/989,792
; FILING DATE: 10-DEC-1992
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 578 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; PCT-US93-11638-2

Query Match 100.0%; Score 1129; DB 5; Length 578;
Best Local Similarity 100.0%; Pred. No. 2.5e-121;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SDAHGTELPSPSPVWFEEFFHHILHWTPIPNQSESTCYEVALRYGIESWNSISNCSQT 60
DB 19 SDAHGTELPSPSPVWFEEFFHHILHWTPIPNQSESTCYEVALRYGIESWNSISNCSQT 78
QY 61 LSYDLTAVTLDLYHSGNGYRVARVDGSRHSNWTVTNTRFSVDEVTLTVGSVNLEIHNGF 120
DB 79 LSYDLTAVTLDLYHSGNGYRVARVDGSRHSNWTVTNTRFSVDEVTLTVGSVNLEIHNGF 138
QY 121 ILGKIQLPRPKMAPANDTYESIFSHFREYEAIRKVPNGFTFTHKKVKHENFSLTSGEV 180
DB 139 ILGKIQLPRPKMAPANDTYESIFSHFREYEAIRKVPNGFTFTHKKVKHENFSLTSGEV 198
QY 181 GFECVQKPSVASRSNKGWSKEECISLTRQ 211
DB 199 GFECVQKPSVASRSNKGWSKEECISLTRQ 229

RESULT 8

US-08-424-788-6
; Sequence 6, Application US/08424788
; Patent No. 5716804
; GENERAL INFORMATION:
; APPLICANT: Moore, Kevin W.
; APPLICANT: Wei, Sherry
; APPLICANT: Ho, Alice Suk-Yue
; TITLE OF INVENTION: MAMMALIAN INTERLEUKIN-10 (IL-10)
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DNAX Research Institute
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA: US/08/424,788
APPLICATION NUMBER: US/08/424,788
FILING DATE: 19-APR-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Ching, Edwin P.
REGISTRATION NUMBER: 34,090
REFERENCE/DOCKET NUMBER: DX0501
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-852-9196
TELEFAX: 415-496-1200
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 557 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-424-788-6

Query Match 98.8%; Score 1115; DB 1; Length 557;
Best Local Similarity 100.0%; Pred. No. 9.6e-120;
Matches 208; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HGTLPSPSPVWPEAFEFHIIHMTPIPNQSESTCYEVALLRYGIESNMSISNCSTLSY 63
DB 1 HGTLPSPSPVWPEAFEFHIIHMTPIPNQSESTCYEVALLRYGIESNMSISNCSTLSY 60
QY 64 DLTAVTLDTLHNSNGYRARRAVDGSRRSNMTVTNTRFSVDEVTLTVGSVNLTHNG 123
DB 61 DLTAVTLDTLHNSNGYRARRAVDGSRRSNMTVTNTRFSVDEVTLTVGSVNLTHNG 120
QY 124 KIQLPRPKMAPANDYESIFSHFREYEIAIRKVPNGFTTHKKVXHEHFSLLTSGEYGF 183
DB 121 KIQLPRPKMAPANDYESIFSHFREYEIAIRKVPNGFTTHKKVXHEHFSLLTSGEYGF 180
QY 184 CVQVPSVASRSNKGMSKEECISLTRQ 211
DB 181 CVQVPSVASRSNKGMSKEECISLTRQ 208

RESULT 9
US-08-424-788-3
Sequence 3, Application US/08424788
Patent No. 5716804
GENERAL INFORMATION:
APPLICANT: Moore, Kevin W.
APPLICANT: Wei, Sherry
APPLICANT: Ho, Alice Suk-yue
TITLE OF INVENTION: MAMMALIAN INTERLEUKIN-10 (IL-10)
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESS: DNAX Research Institute
STREET: 901 California Avenue
CITY: Palo Alto
STATE: California
COUNTRY: USA
ZIP: 94304-1104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/424,788
FILING DATE: 19-APR-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Ching, Edwin P.
REGISTRATION NUMBER: 34,090
REFERENCE/DOCKET NUMBER: DX0501

TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-852-9196
TELEFAX: 415-496-1200
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 559 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-424-788-3

Query Match 53.3%; Score 602; DB 1; Length 559;
Best Local Similarity 57.5%; Pred. No. 1.3e-60;
Matches 122; Conservative 23; Mismatches 63; Indels 4; Gaps 3;

QY 3 AHGTLPSPSPVWPEAFEFHIIHMTPIPNQSESTCYEVALLRYGIESNMSISNC--SQT 60
DB 5 AHGTLPSPSPVWPEAFEFHIIHMTPIPNQSESTCYEVALLRYGIESNMSISNC--SQT 64
QY 61 LSYDLTAVTLDTLHNSNGYRARRAVDGSRRSNMTVTNTRFSVDEVTLTVGSVNLTHNG 119
DB 65 LSCDLTTLTDLHRSYGRARRAVDGSRRSNMTVTNTRFSVDEVTLTVGSVNLTHNG 124
QY 120 FLGKIQLPRPKMAPANDYESIFSHFREYEIAIRKVPNGFTTHKKVXHEHFSLLTSGE 179
DB 125 ILYGTIHPRPPIIPAGDEYEQVFKDLRYKISIRK-SELKNAKRVKQETFTLTVPIG 183
QY 180 VGEFCVQVPSVASRSNKGMSKEECISLTRQ 211
DB 184 VAKFCVQVPSVASRSNKGMSKEECISLTRQ 215

RESULT 10
US-08-424-788-2
Sequence 2, Application US/08424788
Patent No. 5716804
GENERAL INFORMATION:
APPLICANT: Moore, Kevin W.
APPLICANT: Wei, Sherry
APPLICANT: Ho, Alice Suk-yue
TITLE OF INVENTION: MAMMALIAN INTERLEUKIN-10 (IL-10)
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESS: DNAX Research Institute
STREET: 901 California Avenue
CITY: Palo Alto
STATE: California
COUNTRY: USA
ZIP: 94304-1104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/424,788
FILING DATE: 19-APR-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Ching, Edwin P.
REGISTRATION NUMBER: 34,090
REFERENCE/DOCKET NUMBER: DX0501
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-852-9196
TELEFAX: 415-496-1200
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 575 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein

US-08-424-788-2

Query Match 53.3%; Score 602; DB 1; Length 575;
Best Local Similarity 57.5%; Pred. No. 1.3e-60;
Matches 122; Conservative 23; Mismatches 63; Indels 4; Gaps 3;
QY 3 AHGTLPSPSPVWFAEFHILHWTPIPNOSSESTCYEVALLRGYIESWNSISNC--SQT 60
DB 21 AYTGLTSPSPVWFAEFHILHWKPIPNQSESTYVEVALKQYGNSTWNDIHCRAQA 80
QY 61 LSYDLTAVTLDLYH-SNGYRARVAVDGSRHNSNWTNTFRSVDVTLTVGSVNLEIHNG 119
DB 81 LSCDLTFTLDLYHRSYGYRARVAVDQSNQSNWTNTFRSVDVTLTVGSVNLEIHNG 140
QY 120 FILGKIQLPRKMAPANDTYESIFSHFREYEAIRKVPGNFTFTHKKVKHNFSLTSGE 179
DB 141 IYGTIHPRPRTITPAGDEYEQVFKDLRVYKISIRKF-SELKNATKRVKQETFTLTVPIG 199
QY 180 VGEFCVQVKPSVASRSNKGMSKECISLTRQ 211
DB 200 VRKFCVKVLPRLSRINKAEWSEQCLLTITE 231

RESULT 11

US-08-110-683-4
; Sequence 4, Application US/08110683
; Patent No. 5789192
; GENERAL INFORMATION:
; APPLICANT: Moore, Kevin W.
; APPLICANT: Liu, Ying
; APPLICANT: Ho, Alice Suk-Yue
; APPLICANT: Hsu, Di-Hwei
; APPLICANT: Bazan, J. Fernando
; APPLICANT: Tan, Jimmy C.
; APPLICANT: Chou, Chuan-Chu
; TITLE OF INVENTION: Mammalian Receptors for Interleukin-10
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/110,683
; FILING DATE: 23-AUG-1993
; CLASSIFICATION: 436
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/011,066
; FILING DATE: 29-JAN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Ching, Edwin P.
; REGISTRATION NUMBER: 34,090
; REFERENCE/DOCKET NUMBER: DX0335K1
; TELEPHONE: 415-852-9196
; TELEFAX: 415-496-1200
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 575 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-110-683-4

Query Match 53.3%; Score 602; DB 1; Length 575;

Best Local Similarity 57.5%; Pred. No. 1.3e-60;
Matches 122; Conservative 23; Mismatches 63; Indels 4; Gaps 3;
QY 3 AHGTLPSPSPVWFAEFHILHWTPIPNOSSESTCYEVALLRGYIESWNSISNC--SQT 60
DB 21 AYTGLTSPSPVWFAEFHILHWKPIPNQSESTYVEVALKQYGNSTWNDIHCRAQA 80
QY 61 LSYDLTAVTLDLYH-SNGYRARVAVDGSRHNSNWTNTFRSVDVTLTVGSVNLEIHNG 119
DB 81 LSCDLTFTLDLYHRSYGYRARVAVDQSNQSNWTNTFRSVDVTLTVGSVNLEIHNG 140
QY 120 FILGKIQLPRKMAPANDTYESIFSHFREYEAIRKVPGNFTFTHKKVKHNFSLTSGE 179
DB 141 IYGTIHPRPRTITPAGDEYEQVFKDLRVYKISIRKF-SELKNATKRVKQETFTLTVPIG 199
QY 180 VGEFCVQVKPSVASRSNKGMSKECISLTRQ 211
DB 200 VRKFCVKVLPRLSRINKAEWSEQCLLTITE 231

RESULT 12

US-08-477-166-4
; Sequence 4, Application US/08477166
; Patent No. 5863796
; GENERAL INFORMATION:
; APPLICANT: Moore, Kevin W.
; APPLICANT: Liu, Ying
; APPLICANT: Ho, Alice Suk-Yue
; APPLICANT: Hsu, Di-Hwei
; APPLICANT: Bazan, J. Fernando
; APPLICANT: Tan, Jimmy C.
; APPLICANT: Chou, Chuan-Chu
; TITLE OF INVENTION: Mammalian Receptors for Interleukin-10
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; STREET: 901 California Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304-1104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/477,166
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/110,683
; FILING DATE: 23-AUG-1993
; APPLICATION NUMBER: US 08/011,066
; FILING DATE: 29-JAN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Ching, Edwin P.
; REGISTRATION NUMBER: 34,090
; REFERENCE/DOCKET NUMBER: DX0335K1
; TELEPHONE: 415-852-9196
; TELEFAX: 415-496-1200
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 575 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-477-166-4

Query Match 53.3%; Score 602; DB 2; Length 575;
Best Local Similarity 57.5%; Pred. No. 1.3e-60;

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 13, 2003, 15:28:46 ; Search time 29.223 Seconds

(without alignments)
962.115 Million cell updates/sec

Title: US-09-728-911-36

Perfect score: 1129

Sequence: 1 SDAGTELPSPPSVFEAEF.....ASRNKQWMSKECISLTRQ 211

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database : A_Geneset_101002:*

1: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1980.DAT:*
2: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1981.DAT:*
3: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1982.DAT:*
4: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1983.DAT:*
5: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1984.DAT:*
6: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1985.DAT:*
7: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1986.DAT:*
8: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1987.DAT:*
9: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1988.DAT:*
10: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1989.DAT:*
11: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1990.DAT:*
12: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1991.DAT:*
13: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1992.DAT:*
14: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1993.DAT:*
15: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1994.DAT:*
16: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1995.DAT:*
17: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1996.DAT:*
18: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1997.DAT:*
19: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1998.DAT:*
20: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA1999.DAT:*
21: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA2000.DAT:*
22: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA2001.DAT:*
23: /SIDS2/gcgdata/geneeq/geneeq-emb1/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1129	100.0	211	22	Human IL-10 recept
2	1129	100.0	211	23	Human soluble inte
3	1129	100.0	578	15	Human IL-10 recept
4	1129	100.0	578	19	Human IL-10 recept
5	1129	100.0	578	22	Human IL-10 recept
6	602	53.3	575	19	Human IL-10 recept
7	598	53.0	575	15	Human IL-10 recept
8	252.5	22.4	94	22	Human truncated int
9	156	13.8	210	22	Human zcytor16 ext
10	156	13.8	214	23	Human cytokine rec

11	156	13.8	231	22	AAE05048	Human ZCYTO18 solu
12	156	13.8	231	22	AAE02460	Human DNAX cytokin
13	156	13.8	231	22	AAE62657	Human cytokine rec
14	156	13.8	231	23	AAO17381	Human cytokine rec
15	156	13.8	231	23	AAU80000	Human IL-11F/IL-22
16	156	13.8	231	23	ABG34086	Human Pro peptide
17	156	13.8	231	23	AAE17320	Human cytokine rec
18	152	13.5	262	22	AAU09186	Human PRO19598 pol
19	152	13.5	263	23	AAO17382	Human cytokine rec
20	152	13.5	263	23	AAE17321	Human cytokine rec
21	145	12.6	263	23	AAU80324	Human IL-11F/IL-22
22	143	12.7	207	22	AAE85289	Human IL-20 recept
23	143	12.7	207	23	ABG67220	Human IL-20 recept
24	143	12.7	214	22	AAE85287	Human IL-20 recept
25	143	12.7	214	23	ABG67218	Human IL-20 recept
26	143	12.7	217	22	AAE85280	Human IL-20 recept
27	143	12.7	217	23	ABG67211	Human IL-20 recept
28	143	12.7	221	22	AAE85269	Human IL-20 recept
29	143	12.7	221	23	ABG67200	Human IL-20 recept
30	143	12.7	221	23	AAE23354	Human IL-20 recept
31	143	12.7	221	23	AAU92232	Human PRO polypept
32	143	12.7	221	23	AAU12265	Human PRO4978 poly
33	143	12.7	547	22	AAE85279	Human IL-20RA-19 g
34	143	12.7	547	23	ABG67210	Human IL-20RA-19 g
35	143	12.7	547	23	AAE23362	Human IL-20RA EC d
36	143	12.7	553	19	AAW79159	ZCYTO17 cytokine r
37	143	12.7	553	22	ABH11582	Human class II cyt
38	143	12.7	553	22	AAU04058	Human IL-20 recept
39	143	12.7	553	22	AAE85268	Human IL-20 recept
40	143	12.7	553	23	ABG67199	Human IL-20 recept
41	143	12.7	553	23	AAE23353	Human IL-20RA-19 g
42	143	12.7	555	22	AAU04072	Human IL-20RA-19 g
43	143	12.7	559	22	AAE85286	Human IL-20RA-19 g
44	143	12.7	559	23	ABG67217	Human IL-20RA-19 g
45	143	12.7	559	23	AAE23361	Human IL-20RA EC d

ALIGNMENTS

RESULT 1
ID AAB62668 standard; Protein; 211 AA.
XX AAB62668;
AC
XX 23-JUN-2001 (first entry)
DT
XX Human IL-10 receptor polypeptide.
DE
XX Cytokine receptor; zcytor16; IL-11F; antiinflammatory; cytostratic;
XX antitubercular; antitubercular; antitubercular; antitubercular;
KW immunosuppressive; chromosome 6q24.1-25.2; human; interleukin; IL-10.
XX
XX Homo sapiens.
OS
XX WO200140467-A1.
PN
XX 07-JUN-2001.
PD
XX 01-DEC-2000; 2000WO-US32703.
PF
XX 03-DEC-1999; 99US-0169049.
PR 13-SEP-2000; 2000US-0232219.
PR 31-OCT-2000; 2000US-0244610.
XX
XX (ZYMO) ZYMOGENETICS INC.
PA
XX Presnell SR, Xu W, Kindsvogel W, Chen Z;
PI WPI; 2001-356158/37.
XX
XX New soluble cytokine receptor polypeptides and polynucleotides, useful

PT for diagnosing and treating cancer and inflammatory conditions -

XX Claim 46; Page 208; 210pp; English.

XX The invention relates to a human cytokine receptor polypeptide, designated zcytor16. The zcytor16 polypeptide can be expressed by standard recombinant methodology and can bind to IL-TIF (undefined). The zcytor16 protein is useful for: inhibiting IL-TIF induced proliferation or differentiation of hematopoietic cell(s) (progenitors); reducing IL-TIF induced or IL-9 induced inflammation; and suppressing an inflammatory response in a mammal with inflammation. Heteromeric/multimeric receptor polypeptides such as soluble zcytor 16/CRP2-4 can be used to reduce progression and symptoms of cancer. Zcytor16 polypeptides can also be used to detect IL-TIF levels which is indicative of pathological conditions including inflammatory states (e.g. rheumatoid arthritis) and cancer. Antibodies that bind zcytor16 polypeptides and the polypeptides themselves are useful for the treatment of inflammation, inflammatory diseases (e.g. infection, asthma, inflammatory bowel disease, rheumatoid arthritis and atherosclerosis) and autoimmune diseases. The antibodies and zcytor16 polynucleotides are also useful for detecting cancer. The present sequence represents the human interleukin-10 (IL-10) receptor protein which forms a receptor complex with zcytor16.

XX Sequence 211 AA;

Query Match 100.0%; Score 1129; DB 22; Length 211;
Best Local Similarity 100.0%; Pred. No. 6.1e-113;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SDAHGTELPSPSPVWFPEAFFHHILHWTPIPNQSESTCYEVALRYGIESWNSINCSQT 60

Db 1 SDAHGTELPSPSPVWFPEAFFHHILHWTPIPNQSESTCYEVALRYGIESWNSINCSQT 60

QY 61 LSYDLTAVTLDLHNSGYRVARVAVDGRSHSNWTVTNTRFSVDEVTLTGVSVNLEIHNGF 120

Db 61 LSYDLTAVTLDLHNSGYRVARVAVDGRSHSNWTVTNTRFSVDEVTLTGVSVNLEIHNGF 120

QY 121 ILGKIQLPRPKMAPANDTYESIFSHFREYEIAIRKVPNGNFTTHKKVKHNFSLTSGEV 180

Db 121 ILGKIQLPRPKMAPANDTYESIFSHFREYEIAIRKVPNGNFTTHKKVKHNFSLTSGEV 180

QY 181 GFECVQVKSVAASRSGKMGWSKEECISLTRQ 211

Db 181 GFECVQVKSVAASRSGKMGWSKEECISLTRQ 211

RESULT 2

AAU76914

ID AAU76914 standard; Protein; 211 AA.

AC AAU76914;

XX 05-JUN-2002 (first entry)

DE Human soluble interleukin 10 (IL-10) receptor protein.

XX Z-Cyt II; human; cytokine receptor; atopy; psoriasis; receptor;
KW interleukin-T-cell inducible factor; IL-TIF; allergy; asthma;
KW receptor-modulated apoptosis; Th1; immune response; pancreatitis;
KW type I diabetes; IDDM; pancreatic cancer; Graves disease; SLE;
KW inflammatory bowel disease; IBD; Crohn's disease; colon cancer;
KW intestinal cancer; diverticulosis; autoimmune disease; sepsis;
KW multiple sclerosis; MS; systemic lupus erythematosus;
KW myasthenia gravis; rheumatoid arthritis; kidney dysfunction;
KW soluble interleukin 10 receptor.

XX Homo sapiens.

OS WO200212345-A2.

PN 14-FEB-2002.

XX

PF 08-AUG-2001; 2001WO-US24839.

XX 08-AUG-2000; 2000US-223827P.

PR 01-DEC-2000; 2000US-250876P.

XX (ZYMO) ZYMOGENETICS INC.

XX Kindvogel WR, Topouzis S;

PI WPI; 2002-217182/27.

DR New soluble cytokine receptor which binds interleukin-T-cell inducible

XX factor and antagonizes its activity in inflammatory and immune diseases such as cancer, diabetes, asthma, sepsis, psoriasis and autoimmune diseases -

PS Claim 5; Page 116; 117pp; English.

XX This invention relates to the protein and cDNA sequences of a novel soluble cytokine receptor polypeptide designated zcytorII, which binds interleukin-T-cell inducible factor (IL-TIF) or antagonizes IL-TIF activity. The protein of the invention is useful for reducing IL-TIF- or IL-9 induced inflammation, and inhibiting IL-TIF-induced proliferation. The protein is also useful for suppressing an immune response in a mammal exposed to an antigen or pathogen. Soluble zcytorII receptor or heterodimeric polypeptide is useful for enhancing the in vivo killing of target tissues by directly stimulating a zcytorII receptor-modulated apoptotic pathway. IL-TIF is involved in promoting Th1-type immune responses and antagonists of IL-TIF have beneficial use against diseases involving such immune responses. Soluble zcytorII heterodimers are useful as antagonists in inflammatory and immune diseases or conditions such as pancreatitis, type I diabetes (IDDM), pancreatic cancer, Crohn's disease, inflammatory bowel disease (IBD), Crohn's disease, colon and intestinal cancer, diverticulosis, autoimmune disease (e.g. IDDM, multiple sclerosis (MS), systemic lupus erythematosus (SLE), myasthenia gravis, rheumatoid arthritis and kidney sepsis, asthma, allergy and other atopic diseases, psoriasis and kidney dysfunction. Soluble zcytorII receptor or heterodimeric receptor polypeptides are useful in vivo or in diagnostic applications to detect IL-TIF expressing cancers in vivo or in tissue samples and to prepare antibodies. ZcytorII serves as a target for MAB therapy of cancer where an antagonising MAB inhibits cancer growth and targets immune-mediated killing. The present sequence represents the human soluble IL-10 receptor of the invention.

XX Sequence 211 AA;

Query Match 100.0%; Score 1129; DB 23; Length 211;

Best Local Similarity 100.0%; Pred. No. 6.1e-113;

Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SDAHGTELPSPSPVWFPEAFFHHILHWTPIPNQSESTCYEVALRYGIESWNSINCSQT 60

Db 1 SDAHGTELPSPSPVWFPEAFFHHILHWTPIPNQSESTCYEVALRYGIESWNSINCSQT 60

QY 61 LSYDLTAVTLDLHNSGYRVARVAVDGRSHSNWTVTNTRFSVDEVTLTGVSVNLEIHNGF 120

Db 61 LSYDLTAVTLDLHNSGYRVARVAVDGRSHSNWTVTNTRFSVDEVTLTGVSVNLEIHNGF 120

QY 121 ILGKIQLPRPKMAPANDTYESIFSHFREYEIAIRKVPNGNFTTHKKVKHNFSLTSGEV 180

Db 121 ILGKIQLPRPKMAPANDTYESIFSHFREYEIAIRKVPNGNFTTHKKVKHNFSLTSGEV 180

QY 181 GFECVQVKSVAASRSGKMGWSKEECISLTRQ 211

Db 181 GFECVQVKSVAASRSGKMGWSKEECISLTRQ 211

RESULT 3

AAR57138

ID AAR57138 standard; Protein; 578 AA.

XX

AC AAR57138;

XX 08-FEB-1995 (first entry)
DT Interleukin-10 receptor subunit.
DE Interleukin-10 receptor; therapeutic.
XX Homo sapiens.
XX Key Location/Qualifiers
FH 1..216
FT /label= soluble binding fragment
FT 217..243
FT Region /label= hydrophobic membrane-spanning segment
XX WO9413801-A.
XX PD 23-JUN-1994.
XX PF 07-DEC-1993; 93WO-US11638.
XX PR 10-DEC-1992; 92US-0989792.
XX PR 29-JAN-1993; 93US-0011066.
XX PR 23-AUG-1993; 93US-0110683.
XX PA (SCHE) SCHERING CORP.
XX PI Bazan J, Chou C, Ho A, Hsu D, Liu Y, Moore KW;
PI Tan JC;
XX WPI: 1994-234214/28.
XX N-PSDB; AA069214.
XX Nucleic acid encoding mammalian interleukin-10 receptors - are
PT used to develop prods. for therapy of IL-10 disorders and for
PT diagnostic and screening assays
XX Claim 12; Page 59-61; 74pp; English.
XX The protein is used for treating mammals suffering from
CC inappropriate IL-10 response or undesired receptor function.
CC It may be used for screening for receptor ligand agonists and
CC antagonists, and for producing diagnostic or therapeutic agents.
XX Sequence 578 AA;
SQ
Query Match 100.0%; Score 1129; DB 15; Length 578;
Best Local Similarity 100.0%; Pred. No. 2.6e-112; Indels 0; Gaps 0;
Matches 211; Conservative 0; Mismatches 0;
QY 1 SDAGHTELPSPSPVWFEEAFPHHILHMTPIPNQSESTCYEVALLRYGIESWNSISNCST 60
DB 19 SDAGHTELPSPSPVWFEEAFPHHILHMTPIPNQSESTCYEVALLRYGIESWNSISNCST 78
QY 61 LSYDITLAVTLDLVHNSNGYARAVRVDGSRHSNWTNTNRSVDEVTLTVGSVNLTHNGF 120
DB 79 LSYDITLAVTLDLVHNSNGYARAVRVDGSRHSNWTNTNRSVDEVTLTVGSVNLTHNGF 138
QY 121 ILGKIQLPRPKMAPANDTYESIFSHFREYEIAIRKVGNTFTTHKKVKGHEFSLTSGEV 180
DB 139 ILGKIQLPRPKMAPANDTYESIFSHFREYEIAIRKVGNTFTTHKKVKGHEFSLTSGEV 198
QY 181 GEFCVQVKPSVASRSNKGMSKEECISLTRQ 211
DB 199 GEFCVQVKPSVASRSNKGMSKEECISLTRQ 229
RESULT 4
AAW41804
ID AAW41804 standard; Protein; 578 AA.
XX AAW41804;
XX

DT 14-MAY-1998 (first entry)
XX Human IL-10 receptor.
DE Super-activating; human; interleukin-10 receptor; IL-10R;
XX treatment; autoimmune disease; septic shock; toxic shock;
XX infection.
XX Homo sapiens.
XX Key Location/Qualifiers
FH 1..21
FT Peptide /label= sig_peptide
FT Peptide 22..578
FT /label= mat_peptide
XX US5716804-A.
XX PD 10-FEB-1998.
XX PF 19-APR-1995; 95US-0424788.
XX PR 19-APR-1995; 95US-0424788.
XX PA (SCHE) SCHERING CORP.
XX PI Ho AS, Moore KW, Wei S;
PI N-PSDB; AA13208.
XX WPI: 1998-144798/13.
XX N-PSDB; AA13208.
XX Interleukin-10 receptor deletion mutant(s) - with increased
PT sensitivity to IL-10, used to treat autoimmune disease, septic
PT shock, infection, etc.
XX Disclosure; Columns 25-30; 27pp; English.
XX The present sequence was used in the preparation of a novel
CC super-activating mammalian interleukin-10 receptor (IL-10R), having
CC a deletion close to the cytoplasmic membrane domain. Cells
CC expressing such IL-10R mutants can be used in assays for IL-10 or
CC IL-10 agonists or antagonists. They can also be used as carriers
CC for a ligand, agonist or antagonist, as a means to isolate other
CC subunits of the IL-10 receptor, in diagnostic assays or to treat,
CC e.g. autoimmune diseases, septic shock, toxic shock or infections.
CC The mutants have greater sensitivity to IL-10, as assayed by cell
CC proliferation, than wild-type IL-10R, preferably by a factor of at
CC least 5, especially at least 20.
XX Sequence 578 AA;
SQ
Query Match 100.0%; Score 1129; DB 19; Length 578;
Best Local Similarity 100.0%; Pred. No. 2.6e-112; Indels 0; Gaps 0;
Matches 211; Conservative 0; Mismatches 0;
QY 1 SDAGHTELPSPSPVWFEEAFPHHILHMTPIPNQSESTCYEVALLRYGIESWNSISNCST 60
DB 19 SDAGHTELPSPSPVWFEEAFPHHILHMTPIPNQSESTCYEVALLRYGIESWNSISNCST 78
QY 61 LSYDITLAVTLDLVHNSNGYARAVRVDGSRHSNWTNTNRSVDEVTLTVGSVNLTHNGF 120
DB 79 LSYDITLAVTLDLVHNSNGYARAVRVDGSRHSNWTNTNRSVDEVTLTVGSVNLTHNGF 138
QY 121 ILGKIQLPRPKMAPANDTYESIFSHFREYEIAIRKVGNTFTTHKKVKGHEFSLTSGEV 180
DB 139 ILGKIQLPRPKMAPANDTYESIFSHFREYEIAIRKVGNTFTTHKKVKGHEFSLTSGEV 198
QY 181 GEFCVQVKPSVASRSNKGMSKEECISLTRQ 211
DB 199 GEFCVQVKPSVASRSNKGMSKEECISLTRQ 229
RESULT 5

AAB82983
 ID AAB82983 standard; Protein; 578 AA.
 AC AAB82983;
 XX
 XX 21-DEC-2001 (first entry)
 XX
 XX Human interleukin 10 receptor subunit alpha.
 XX
 XX Interleukin 10 receptor; IL-10RA; human; Crohn's disease;
 KW inflammatory bowel disease; ulcerative colitis; autoimmune disease;
 KW systemic lupus erythematosus; rheumatoid arthritis; septic shock;
 KW coxic shock; infection; diagnosis; therapy.
 XX
 XX Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FH Peptide 1..21
 FT /label= Signal_peptide
 FT Protein 22..578
 FT /label= Mature_protein
 FT Misc-difference 159
 FT /note= "site of S159G substitution"
 FT Misc-difference 351
 FT /note= "site of G351R substitution"
 XX
 XX WO200164713-A2.
 XX
 XX 07-SEP-2001.
 XX
 XX 01-MAR-2001; 2001WO-EP02296.
 XX
 XX 01-MAR-2000; 2000US-186125P.
 XX
 XX (GASC/) GASCHE C.
 PA (ZAKERI) ZAKERI S M.
 XX
 XX Gasche C, Zakeri SM, Reinisch W;
 PI WPI; 2001-638950/73.
 XX N-PSDB; AAH27020, AAH27023.
 XX
 XX New mammalian interleukin 10 receptor variants, useful for screening
 PT agonists and antagonists of the IL-10 receptor ligands or for producing
 PT reagents for diagnosing or treating e.g. autoimmune conditions, or
 PT septic shock conditions -
 XX
 XX Claim 8; Page 43; 58pp; English.
 XX
 XX The present sequence is that of the human interleukin 10 receptor
 CC alpha subunit (IL-10RA). The invention relates to variants of
 CC the receptor that display at least 3-fold modified, e.g. greater,
 CC response to ligand binding. The variants have an amino acid
 CC substitution at position Gly351 (preferably a charged amino acid,
 CC especially Arg), Ser159 (preferably an uncharged amino acid,
 CC especially Gly) or from position Leu-62 of the present sequence.
 CC Preferred polypeptides (see AAB82983-87) are of at least 12 amino
 CC acids and comprise at least 3 residues matching each side of, and
 CC flanking, a substitution of standard human IL-10RA at Gly351,
 CC Ser159 or Leu61. The invention provides variant human IL-10RA
 CC polypeptides and nucleic acids encoding them. The variants are
 CC useful in preparing antibodies, agonists and antagonists useful for
 CC diagnosing or treating various IL-10 or receptor-related medical
 CC conditions, e.g. Crohn's disease, inflammatory bowel disease,
 CC ulcerative colitis, autoimmune conditions such as systemic lupus
 CC erythematosus and rheumatoid arthritis, septic and toxic shock, and
 CC infection. Antibodies or nucleic acids that can distinguish between
 CC the different forms of the receptor are useful for therapeutic
 CC prognosis, for providing differential functional information on the
 CC respective variants, or for determining therapeutical treatment.
 XX
 XX Sequence 578 AA;

Query Match 100.0%; Score 1129; DB 22; Length 578;
 Best Local Similarity 100.0%; Pred. No. 2.6e-112;
 Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 SDAHGTELPSPSPVWFEEAFPHHLLHWTPIPNQSESTCYEVALLRYGIESWNSISNCSQT 60
 DB 19 SDAHGTELPSPSPVWFEEAFPHHLLHWTPIPNQSESTCYEVALLRYGIESWNSISNCSQT 78
 QY 61 LSYDLTAVTLDLYHNGYRARVAVDGRHSNWTVTNTRFSVDVTLTVGSVNLEIHNGF 120
 DB 79 LSYDLTAVTLDLYHNGYRARVAVDGRHSNWTVTNTRFSVDVTLTVGSVNLEIHNGF 138
 QY 121 ILGKIQLPRPKMAPANDTYESIFSHFREYEIAIRKVPNGNFTFTHKKVKHNFSLTSGEV 180
 DB 139 ILGKIQLPRPKMAPANDTYESIFSHFREYEIAIRKVPNGNFTFTHKKVKHNFSLTSGEV 198
 QY 181 GEFCVQVKPSVASRSNKGWSKEECISLTRQ 211
 DB 199 GEFCVQVKPSVASRSNKGWSKEECISLTRQ 229
 RESULT 6
 AAW41803
 ID AAW41803 standard; Protein; 575 AA.
 XX
 AC AAW41803;
 XX
 XX 14-MAY-1998 (first entry)
 XX
 XX Mouse IL-10 receptor.
 XX
 KW Super-activating; mouse; murine; interleukin-10 receptor; IL-10R;
 KW treatment; autoimmune disease; septic shock; toxic shock;
 KW infection.
 XX
 XX Mus sp.
 XX
 FH Key Location/Qualifiers
 FT Peptide 1..16
 FT /label= sig_peptide
 FT Peptide 17..575
 FT /label= mat_peptide
 XX
 XX US5716804-A.
 PN
 XX
 XX 10-FEB-1998.
 PD
 XX
 XX 19-APR-1995; 95US-0424788.
 PF
 XX
 XX 19-APR-1995; 95US-0424788.
 PR
 XX (SCHE) SCHERING CORP.
 PA
 XX Ho AS, Moore KW, Wei S;
 PI WPI: 1998-144798/13.
 XX N-PSDB; AAV13207.
 DR
 XX Interleukin-10 receptor deletion mutant(s) - with increased
 PT sensitivity to IL-10, used to treat autoimmune disease, septic
 PT shock, infection, etc.
 XX
 XX Claim 2; Columns 13-18; 27pp; English.
 PS
 XX The present sequence was used in the preparation of a novel
 CC super-activating mammalian interleukin-10 receptor (IL-10R), having
 CC a deletion close to the cytoplasmic membrane domain. Cells
 CC expressing such IL-10R mutants can be used in assays for IL-10 or
 CC IL-10 agonists or antagonists. They can also be used as carriers
 CC for a ligand, agonist or antagonist, as a means to isolate other
 CC subunits of the IL-10 receptor, in diagnostic assays or to treat,
 CC e.g. autoimmune diseases, septic shock, toxic shock or infections.
 CC The mutants have greater sensitivity to IL-10, as assayed by cell

CC proliferation, than wild-type IL-10R, preferably by a factor of at
 CC least 5, especially at least 20.

XX Sequence 575 AA;

Query Match 53.3%; Score 602; DB 19; Length 575;
 Best Local Similarity 57.5%; Pred. No. 1.1e-55;
 Matches 122; Conservative 23; Mismatches 63; Indels 4; Gaps 3;

QY 3 AHGTELPSPSPVWFPEAFPHHILHTWPIPNQSESTCYEVALIRGIESMNSISNC--SQT 60
 DB 21 AYGTELPSPSPVWFPEAFPHHILHTWPIPNQSESTCYEVALIRGIESMNSISNC--SQT 60
 QY 61 LSYDTLATVLDLYH-SNGRRARVAVDGSRRHNTVTNTPRSVDEVTLTVGSVNLEIHNG 119
 DB 81 LSCDITFTFLDLYHSYGRARAVAVDGSRRHNTVTNTPRSVDEVTLTVGSVNLEIHNG 140
 QY 120 FLGKIQLPRPMAPANDTYESIFSHFREYEAIRKVPGNFTTHKKVKGHEFSLTSGE 179
 DB 141 IYGTIHPRPRTITPAGDEYEQVKDLRYKISIRKF-SELKNATKRVKQETFTLTVPIG 199
 QY 180 VGEPCVQVPSVASRSNKGMSKECISLTRQ 211
 DB 200 VRKFCVKVLPRLSHRINKAEWSEQCULLITTE 231

RESULT 7

AAR57139
 ID AAR57139 standard; Protein; 575 AA.

XX AAR57139;

DT 08-FEB-1995 (first entry)

DE Interleukin-10 receptor subunit.

KM Interleukin-10 receptor; therapeutic.

OS Mus musculus.

PN MO9413801-A.

PD 23-JUN-1994.

PF 07-DEC-1993; 93WO-US11638.

PR 10-DEC-1992; 92US-09889732.

PR 29-JAN-1993; 93US-0011066.

PR 23-AUG-1993; 93US-0110683.

PA (SCHE) SCHERING CORP.

PI Bazan J, Chou C, Ho A, Hsu D, Liu Y, Moore KW;

PI Tan JC;

DR WPI: 1994-234214/28.

DR N-PSDB; AAQ69215.

PS Nucleic acid encoding mammalian interleukin-10 receptors - are

PT used to develop prods. for therapy of IL-10 disorders and for

PT diagnostic and screening assays

XX Claim 12; Page 65-67; 74pp; English.

XX The protein is used for treating mammals suffering from

CC inappropriate IL-10 response or undesired receptor function.

CC It may be used for screening for receptor ligand agonists and

CC antagonists, and for producing diagnostic or therapeutic agents.

Matches 121; Conservative 24; Mismatches 63; Indels 4; Gaps 3;

QY 3 AHGTELPSPSPVWFPEAFPHHILHTWPIPNQSESTCYEVALIRGIESMNSISNC--SQT 60
 DB 21 AYGTELPSPSPVWFPEAFPHHILHTWPIPNQSESTCYEVALIRGIESMNSISNC--SQT 60
 QY 61 LSYDTLATVLDLYH-SNGRRARVAVDGSRRHNTVTNTPRSVDEVTLTVGSVNLEIHNG 119
 DB 81 LSCDITFTFLDLYHSYGRARAVAVDGSRRHNTVTNTPRSVDEVTLTVGSVNLEIHNG 140
 QY 120 FLGKIQLPRPMAPANDTYESIFSHFREYEAIRKVPGNFTTHKKVKGHEFSLTSGE 179
 DB 141 IYGTIHPRPRTITPAGDEYEQVKDLRYKISIRKF-SELKNATKRVKQETFTLTVPIG 199
 QY 180 VGEPCVQVPSVASRSNKGMSKECISLTRQ 211
 DB 200 VRKFCVKVLPRLSHRINKAEWSEQCULLITTE 231

RESULT 8

AAB82984
 ID AAB82984 standard; Protein; 94 AA.

XX AAB82984;

DT 21-DEC-2001 (first entry)

DE Human truncated interleukin 10 receptor subunit alpha.

KM Interleukin 10 receptor; IL-10RA; human; Crohn's disease;

KM inflammatory bowel disease; ulcerative colitis; autoimmune disease;

KM systemic lupus erythematosus; rheumatoid arthritis; septic shock;

OS Homo sapiens.

FN Key Location/Qualifiers

FT Peptide 1..21 /label= Signal_peptide

FT Protein 22..94 /label= Mature_protein

PN MO200164713-A2.

PD 07-SEP-2001.

PF 01-MAR-2001; 2001WO-EP02296.

PR 01-MAR-2000; 2000US-186125P.

PA (GASC/) GASCHE C.

PA (ZAKER/) ZAKERI S M.

PI Gasche C, Zakeri SM, Reinisch W;

PI WPI: 2001-638950/73.

DR N-PSDB; AAH27022.

PS New mammalian interleukin 10 receptor variants, useful for screening

PT agents and antagonists of the IL-10 receptor ligands or for producing

PT reagents for diagnosing or treating e.g. autoimmune conditions, or

PT septic shock conditions -

XX Claim 8; Page 45; 58pp; English.

XX The present sequence is that of a truncated form of the human

CC interleukin 10 receptor alpha subunit (IL-10RA). A G to A

CC substitution in an acceptor splice site of the IL-10RA gene

CC causes a mutation which leads to exon-skipping during the synthesis

CC of IL-10RA mRNA. The encoded protein sequence comprises only 62

CC amino acids that correspond to standard IL-10RA (see AAB82983)

CC followed by an altered sequence of 32 amino acids. It is assumed

CC that an individual with a homozygotic form of this mutation lacks

CC a functional receptor complex. The mutation was detected in a
 CC heterozygotic manner in 1 healthy donor and was not found in any
 CC Crohn's disease patient. The invention provides variant human
 CC IL-10RA polypeptides that have an amino acid substitution at
 CC position Glv351 and/or Ser159 or from position Leu62 of the
 CC standard IL-10RA sequence. They display at least 3-fold modified,
 CC e.g. greater, response to ligand binding than the standard receptor.
 CC They are useful in preparing reagents, including antibodies,
 CC agonists and antagonists useful for diagnosing or treating various
 CC IL-10 or receptor-related medical conditions, e.g. Crohn's disease,
 CC inflammatory bowel disease, ulcerative colitis, autoimmune
 CC conditions such as systemic lupus erythematosus and rheumatoid
 CC arthritis, septic and toxic shock, and infection. Antibodies that
 CC can distinguish between the different forms of the receptor are
 CC useful for therapeutic prognosis, for providing differential
 CC functional information on the respective variants, or for
 CC determining therapeutic treatment.

XX Sequence 94 AA;

Query Match 22.4%; Score 252.5; DB 22; Length 94;
 Best Local Similarity 90.2%; Pred. No. 3.1e-19;
 Matches 46; Conservative 1; Mismatches 3; Indels 1; Gaps 1;

QY 1 SDAHGTELPSPSVWFEEAFHHILHWTPIPNQSESTCYEVALRYGIESW 51
 |||||
 DB 19 SDAHGTELPSPSVWFEEAFHHILHWTPIPNQSESTCYEVALLS-DSDSW 68

RESULT 9
 AAB62663

ID AAB62663 standard; Protein; 210 AA.

XX AAB62663;

DT 23-JUL-2001 (first entry)

DE Human zcytor16 extracellular domain fragment (residues 22-231).

KW Cytokine receptor; zcytor16; IL-TIF; antiinflammatory; cytostatic;
 KW antirheumatic; antiarthritic; antiasthmatic; antiatherosclerotic;
 KW immunosuppressive; chromosome 6q24.1-25.2; human.

XX Homo sapiens.

OS WO200140467-A1.

PN 07-JUN-2001.

PD 01-DEC-2000; 2000WO-US32703.

PF 03-DEC-1999; 99US-0169049.

PR 13-SEP-2000; 2000US-0232219.

PR 31-OCT-2000; 2000US-0244610.

XX (ZYMO) ZYMOGENETICS INC.

PA Presnell SR, Xu W, Kindsvogel W, Chen Z;

PI WPI; 2001-356158/37.

DR New soluble cytokine receptor polypeptides and polynucleotides, useful

PT for diagnosing and treating cancer and inflammatory conditions -

XX Claim 1; Page 193; 210pp; English.

XX The invention relates to a human cytokine receptor polypeptide,
 CC designated zcytor16. The zcytor16 polypeptide can be expressed by
 CC standard recombinant methodology and can bind to IL-TIF (undefined). The
 CC zcytor16 protein is useful for: inhibiting IL-TIF induced proliferation
 CC or differentiation of hematopoietic cell(s) (progenitors); reducing
 CC IL-TIF induced or IL-9 induced inflammation; and suppressing an
 CC inflammatory response in a mammal with inflammation. Heteromeric/

CC multimeric receptor polypeptides such as soluble zcytor 16/CRF2-4 can be
 CC used to reduce progression and symptoms of cancer. Zcytor16 polypeptides
 CC can also be used to detect IL-TIF levels which is indicative of
 CC pathological conditions including inflammatory states (e.g. rheumatoid
 CC arthritis) and cancer. Antibodies that bind zcytor16 polypeptides and the
 CC polypeptides themselves are useful for the treatment of inflammation,
 CC inflammatory diseases (e.g. infection, asthma, inflammatory bowel
 CC disease, rheumatoid arthritis and atherosclerosis) and autoimmune
 CC diseases. The antibodies and zcytor16 polynucleotides are also useful
 CC for detecting cancer. The present sequence represents the human zcytor16
 CC extracellular domain fragment.

XX Sequence 210 AA;

Query Match 13.8%; Score 156; DB 22; Length 210;
 Best Local Similarity 26.7%; Pred. No. 2.4e-08;
 Matches 58; Conservative 35; Mismatches 88; Indels 36; Gaps 11;

QY 11 PPSVMFEAEFFHHILHWTPIPNQSESTCYEVALRYGIESMNSISNC--SQTLSYDLTA 67
 |||||
 DB 10 PQRVQFSRNFHILQWQGRALTCGNSSVYFYQYKIGORQKNKEDCWGTOELSCDLTS 69
 |||||
 QY 68 VTLDLVHSHNGYRARVRANDGSHSNWTVNTTFRS-----VDEVTLTVGSVNLEIHNGFI 121
 |||||
 DB 70 ETSDI--QEPYGYGRVRAASAGSYSEWSMT-PRFTPWETKIDPPVMNITQV-----NGSL 121
 |||||
 QY 122 LGKIQLP-----RPKMAPANDTVESIFSHFREYEIAIRKVPNGNFTFTHKKVKHENSFL 174
 |||||
 DB 122 LVTLHAPNLPRYQKEKNVSIEDYVELLYRVF-IINSLEREQKQYEGAHRAVEIALTP 180
 |||||

QY 175 LTSGEVGEFCVQV---KPSVASRSNKGMMWKEECISL 208

DB 181 HSS-----YCVVAEIQPMLDRRSQR---SEERCVEI 209

RESULT 10

AAB17319

ID AAB17319 standard; Protein; 214 AA.

XX AAB17319;

DT 18-APR-2002 (first entry)

XX Human cytokine receptor protein, sbg456548Cytora #1.

XX Human; therapy: wound healing disorder; vaccine; cancer; infection;
 KW autoimmune disorder; haematopoietic disorder; inflammation; arthritis;
 KW Parkinson's disease; Huntington's chorea; schizophrenia; antiarrhythmic;
 KW multiple sclerosis; Alzheimer's disease; analgesic; cardiac; asthma;
 KW ischaemia; stroke; AIDS; bone disease; atherosclerosis; brain disorder;
 KW depression; cardiovascular disease; myocardial infarction; renal failure;
 KW respiratory disease; liver disorder; Fanconi's syndrome; spleen disorder;
 KW type II diabetes mellitus; skeletal muscle disorder; immunosuppressive;
 KW hypersplenism; renal disease; hypoglycaemia; gastrointestinal disease;
 KW neutropenic; cirrhosis; Hodgkin's disease; neuroleptic; antiinflammatory;
 KW haemostatic; vulvulery; anticonvulsant; antirheumatic; neuroprotective;
 KW nephrotropic; hypotensive; vasotropic; cytostatic; cerebroprotective;
 KW allergy; cytokine receptor.

XX Homo sapiens.

OS WO200198342-A1.

PN 27-DEC-2001.

PD 22-JUN-2001; 2001WO-US19929.

PF 22-JUN-2000; 2000US-213156P.

PR 22-JUN-2000; 2000US-213161P.

XX (SMIK) SMITHKLINE BEECHAM CORP.

PA (SMIK) SMITHKLINE BEECHAM PLC.

PA (GLAX) GLAXO GROUP LTD.

XX Agatwal P, Cogswell JP, Kabnic KS, Lai Y, Martensen SA,
 PI Murdoch PR, Smith RF, Strum JC, Xiang Z, Xie Q, Rizni SK;
 XX WPI: 2002-139783/18.
 DR N-PSDB; AAD27814.
 XX
 PT Novel secreted and membrane-associated polypeptides and polynucleotides
 PT useful for preventing, ameliorating or correcting dysfunction or
 PT disease including diabetes, cancer, hypertension and growth
 PT abnormalities
 XX
 PS Claim 1: Page 122, 138pp: English.
 XX
 CC The invention relates to secreted and membrane-associated polypeptides
 CC and polynucleotides. The sequences of the invention are useful in
 CC diagnostic assays for detecting diseases associated with inappropriate
 CC activity or levels of these polynucleotides, and in identifying their
 CC agonists and antagonists that are potentially useful in therapy. The
 CC sequences of the invention are useful as vaccines for inducing
 CC immunological response. The sequences of the invention are useful for
 CC treating cancers, infections, autoimmune disorders, haematopoietic
 CC disorders, wound healing disorders, cholesterol ester storage disease,
 CC inflammation, congenital muscular dystrophy, junctional epidermolysis
 CC bullosa, Parkinson's disease, Huntington's chorea, multiple sclerosis,
 CC viral and bacterial infections, Alzheimer's disease, asthma, arthritis,
 CC allergies, psoriasis, inflammatory bowel disease, transplant rejection,
 CC graft versus host disease, ischaemia, stroke, acute respiratory disease
 CC syndrome, restenosis, brain injury, AIDS, bone diseases, atherosclerosis,
 CC brain disorders including paraneoplastic palsy, myotonic dystrophy,
 CC depression, anxiety disorders and sleep disorders, cardiovascular
 CC diseases including congestive heart failure and myocardial infarction,
 CC respiratory diseases including chronic obstructive pulmonary disease,
 CC acute bronchitis and adult respiratory distress syndrome, liver disorders
 CC including hypercholesterolemia, hypertriglyceridemia, cirrhosis, viral
 CC and non-viral hepatitis, type II diabetes mellitus, renal disease
 CC including acute and chronic renal failure, glomerulonephritis, Fanconi's
 CC syndrome, cystinuria, skeletal muscle disorders including hypoglycaemia
 CC and tendinitis, gastrointestinal diseases including intestinal
 CC obstruction and tropical sprue, spleen disorders including hypersplenism,
 CC Hodgkin's disease and malignant lymphoma, testicular cancer, male
 CC reproductive diseases including low testosterone and male infertility.
 CC The present sequence is human cytokine receptor.
 CC
 XX
 SQ Sequence 214 AA;
 Query Match 13.8%; Score 156; DB 23; Length 214;
 Best Local Similarity 26.7%; Pred. No. 2.4e-08;
 Matches 58; Conservative 35; Mismatches 88; Indels 36; Gaps 11;
 QY 11 PPSWFEAEFFHHILHMP-IPNOSSESTCEVALRIGIESWNSISNC--SQTLSYDLTA 67
 DB 14 PQRVQFSNFFNILOMOPGRALTGNSVYFYQKIYQOROKNKEDCNGOELSCDLTS 73
 QY 68 VTLIDYHNSNGYRARVADGSRHSNMTVTNTRFS-----VDEVTLTGVSVNLEIHNGFI 121
 DB 74 ETSDDI--QEPYIGRVRAASAGSYSEWSMT-PRFTPMWETKIDPVMNITGV-----NGSL 125
 QY 122 LGRKIQLP-----RPKMAPANDYTESIFSHFREYEIAIRKVPNGFTTHKKYKHENFSL 174
 DB 126 LVILHAPNLPYRQKRNKNSIEDYIELLYRVF-IINNSLEKQKQYEGAHRAVEIEALTLP 184
 QY 175 LNSGEVGEFCVGV--KPSVASRSNKGWMSKEECISL 208
 DB 185 HSS-----YCVVAEIVQPMIDRRSQR---SEBRCEVEI 213

RESULT 11
 AAE05048
 ID AAE05048 standard; Protein; 231 AA.
 XX
 AC AAE05048;

XX 10-SEP-2001 (first entry)
 XX
 DE Human ZCYTO18 soluble receptor antagonist, zcytor16 protein.
 XX
 KW Human; cytosolic; cytokine; ZCYTO18 protein; genetic abnormality;
 KW cancer; inflammation; gene therapy; zcytor16.
 XX
 OS Homo sapiens.
 XX
 PN WO200146422-A1.
 PD 28-JUN-2001.
 XX
 PF 22-DEC-2000; 2000WO-US35308.
 XX
 PR 23-DEC-1999; 99US-0471767.
 PR 01-DEC-2000; 2000US-0250841.
 XX
 PA (ZYMO) ZYMOGENETICS INC.
 XX
 PI Presnell SR, Kindsvogel W;
 XX
 DR WPI: 2001-408648/43.
 DR N-PSDB; AAD09745.
 XX
 PT Novel human cytokine polypeptide, ZCYTO18, useful for treating cancer -
 XX
 PS Example 13a; Page 158-159; 167pp: English.
 XX
 CC The patent discloses novel human cytokine, ZCYTO18 protein and its
 CC corresponding DNA. ZCYTO18 protein induces proliferation of cells
 CC expressing zcytor11, a receptor for ZCYTO18 or induces cytotoxicity
 CC in K562 cells. ZCYTO18 DNA is useful for detecting a genetic
 CC abnormality in a patient. ZCYTO18 DNA and its antibodies are useful
 CC for detecting cancer and inflammation. ZCYTO18 protein is useful for
 CC killing cancer cells. It is useful for increasing platelets in a
 CC patient or injured tissue. It is also used in gene therapy.
 CC The present sequence is human zcytor16, which is a naturally expressed
 CC soluble receptor antagonist of ZCYTO18 protein.
 CC
 XX
 SQ Sequence 231 AA;
 Query Match 13.8%; Score 156; DB 22; Length 231;
 Best Local Similarity 26.7%; Pred. No. 2.7e-08;
 Matches 58; Conservative 35; Mismatches 88; Indels 36; Gaps 11;
 QY 11 PPSWFEAEFFHHILHMP-IPNOSSESTCEVALRIGIESWNSISNC--SQTLSYDLTA 67
 DB 31 PQRVQFSNFFNILOMOPGRALTGNSVYFYQKIYQOROKNKEDCNGOELSCDLTS 90
 QY 68 VTLIDYHNSNGYRARVADGSRHSNMTVTNTRFS-----VDEVTLTGVSVNLEIHNGFI 121
 DB 91 ETSDDI--QEPYIGRVRAASAGSYSEWSMT-PRFTPMWETKIDPVMNITGV-----NGSL 142
 QY 122 LGRKIQLP-----RPKMAPANDYTESIFSHFREYEIAIRKVPNGFTTHKKYKHENFSL 174
 DB 143 LVILHAPNLPYRQKRNKNSIEDYIELLYRVF-IINNSLEKQKQYEGAHRAVEIEALTLP 201
 QY 175 LNSGEVGEFCVGV--KPSVASRSNKGWMSKEECISL 208
 DB 202 HSS-----YCVVAEIVQPMIDRRSQR---SEBRCEVEI 230

RESULT 12
 AAE02460
 ID AAE02460 standard; Protein; 231 AA.
 XX
 AC AAE02460;
 XX
 DT 10-AUG-2001 (first entry)
 XX
 DE Human DNAX cytokine receptor subunit 4.2 (DCRS4.2).

XX Human; immunomodulator; DNAX cytokine receptor subunit 4.2; DCRS4.2;
KW therapy; immunological disorder; drug screening; cell development;
KW chromosome 6q24.1-25.2.
XX
OS Homo sapiens.
XX
XX
FH Key Location/Qualifiers
FT Peptide 1..21 /label= Signal-peptide
FT Protein 22..231
FT /label= DCRS4.2
FT /note= "Human mature DNAX cytokine receptor
FT subunit 4.2"
XX
PN WO200136467-A2.
XX
XX
PD 25-MAY-2001.
XX
PF 16-NOV-2000; 2000WO-US31363.
XX
XX 18-NOV-1999; 99US-0443060.
PR 13-DEC-1999; 99US-0170320.
XX
XX (SCHE) SCHERING CORP.
XX
XX Gorman DM;
PI
DR WPI; 2001-343800/36.
DR N-PSDB; AAD06414.
XX
XX New mammalian receptor proteins related to cytokine receptors, useful
PT for regulating cell development and for diagnosis and treatment of
PT immunological disorders
XX
XX Claim 3; Page 23; 124pp; English.
PS
XX
XX The present sequence is human DNAX cytokine receptor subunit 4.2
CC (DCRS4.2). DCRS4 gene is located on chromosome 6q24.1-25.2.
CC Cytokine receptors, fragments and antibodies are useful for treating
CC immunological disorders. DCRS3 (50R), DCRS4 (cytor) or fragments are
CC useful in drug screening to identify compounds having binding affinity
CC to the receptor subunit. Modulators of DCRS are useful for modulating
CC the physiology or development of a cell or tissue culture cells. A
CC purified DCRS is useful as a reagent to detect antibodies generated in
CC response to the presence of elevated levels of expression, or
CC immunological disorders which lead to production of antibody to the
CC endogenous receptor. Cytokine receptor sequences are useful as probes
CC for detecting levels of the cytokine receptor in patients suspected of
CC having an immunological disorder. Antibodies have therapeutic value, are
CC useful as potent antagonist, in detecting or quantifying ligands, for
CC isolating DCRS proteins and peptides, to screen expression libraries for
CC particular expression products, to raise anti-idiotypic antibodies and
CC for detecting or diagnosing various immunological conditions related to
CC expression of the protein or cells which express the protein.
XX
XX Sequence 231 AA;
SQ
Query Match 13.8%; Score 156; DB 22; Length 231;
Best Local Similarity 26.7%; Pred. No. 2.7e-08;
Matches 58; Conservative 35; Mismatches 88; Indels 36; Gaps 11;
QY 11 PPSVWFEEAFHHILHWTPT-IPNQSSTCYEVALLRVIGIESWNISNC--SQTLSYDLTA 67
DB 31 PORVQFSRNFHNLQWFGRLTGNSSVYVQYKIYQQRQWKNKDCWGQTQELSCDLTS 90
QY 68 VTLDLYHSGVRYARVADGSRHSNWTVTNFRS-----VDEVTLTGVSNLEIHNGFI 121
DB 91 ETSDI--GEPIYGRVRAASASYSWSMT-PRFTPWETKIDPPVMAITQV-----NGSL 142
QY 122 LGKIQLP-----RPKNMAPNDTYESIFSHFREYIEAIRKVPNGNFTTHKKVKHFNFL 174
DB 143 LVILHAPNLPYRQKEKNVSTIEDYELLYRVF-INNSLEKEQVYEGAHRAVEIEALT 201

QY 175 LTSGEVGECEVQV---KPSVASRSNKGWMSKEECISL 208
DB 202 HSS-----YCVVAEYIYQPMLEDRSRQ---SEERCVEI 230

RESULT 13

AAB62657
ID AAB62657 standard; Protein; 231 AA.

XX
AC AAB62657;

XX
DT 23-JUL-2001 (first entry)

XX
DE Human cytokine receptor, zcytor16.

KW Cytokine receptor; zcytor16; IL-TIF; antiinflammatory; cytostatic;
KW antirheumatic; antiarthritic; antiasthmatic; antiatherosclerotic;
KW immunosuppressive; chromosome 6q24.1-25.2; human.

XX
OS Homo sapiens.

FH Key Location/Qualifiers
FT Domain 22..108
FT /note= "Ig domain 1"

FT Domain 22..231
FT /note= "extracellular domain"

FT Domain 112..210

FT /note= "Ig domain 2"

XX
PN WO200140467-A1.

XX
PD 07-JUN-2001.

XX
PF 01-DEC-2000; 2000WO-US32703.

XX
PR 03-DEC-1999; 99US-0169049.

PR 13-SEP-2000; 2000US-0232219.

XX
PR 31-OCT-2000; 2000US-0244610.

XX
PA (ZYMO) ZYMOGENETICS INC.

XX
PI Presnell SR, Xu W, Kindsvogel W, Chen Z;

XX
DR WPI; 2001-356159/37.

XX
DR N-PSDB; AAF83735.

XX New soluble cytokine receptor polypeptides and polynucleotides, useful
PT for diagnosing and treating cancer and inflammatory conditions -

XX
PS Claim 1; Page 186-188; 210pp; English.

XX The invention relates to a human cytokine receptor polypeptide,
CC designated zcytor16. The zcytor16 polypeptide can be expressed by
CC standard recombinant methodology and can bind to IL-TIF (undefined). The
CC zcytor16 protein is useful for: inhibiting IL-TIF induced proliferation
CC or differentiation of hematopoietic cell(s) (progenitors); reducing
CC IL-TIF induced or IL-9 induced inflammation; and suppressing an
CC inflammatory response in a mammal with inflammation. Heteromeric/
CC multimeric receptor polypeptides such as soluble zcytor 16/CRF2-4 can be
CC used to reduce progression and symptoms of cancer. Zcytor16 polypeptides
CC can also be used to detect IL-TIF levels which is indicative of
CC pathological conditions including inflammatory states (e.g. rheumatoid
CC arthritis) and cancer. Antibodies that bind zcytor16 polypeptides and the
CC polypeptides themselves are useful for the treatment of inflammation,
CC inflammatory diseases (e.g. infection, asthma, inflammatory bowel
CC disease, rheumatoid arthritis and atherosclerosis) and autoimmune
CC diseases. The antibodies and zcytor16 polynucleotides are also useful
CC for detecting cancer. The present sequence represents the human
XX zcytor16 protein.

XX
SQ Sequence 231 AA;

Query Match 13.8%; Score 156; DB 22; Length 231;
 Best Local Similarity 26.7%; Pred. No. 2.7e-08;
 Matches 58; Conservative 35; Mismatches 88; Indels 36; Gaps 11;

QY 11 PPSVFEAEFFHILHMT-IPNQSSTCYEVALLRGIESMNSISNC--SQTLSYDLTA 67
 DB 31 PQRVQOSNRFNHILOMOPGRALTGSSVYFQYKIQGRQKKNKEDCWTGDELSCDLTS 90
 QY 68 VTLDLHNSNGYRARVAVDGRSHSNMTVTNTRFS-----VDEVTLTGVSVNLIEHNGFI 121
 DB 91 ETSDI--GEPYGRVRAAASAGSYSEMSMT-PRFTPMWETKIDPPVNMITQV-----NGSL 142
 QY 122 LKGIQCP-----RPKMAPNDYTESISFHFREYEIAIRKVPGNFTTHKKVGHENFSL 174
 DB 143 LVTLAPNLPYRYOKKKNVSIEDYELLYRVF-IINNSLEKQKVEGAGHRAVEIEALTP 201
 QY 175 LTSGEVGEFCVQV--KPSVASRSNKGMSKECISL 208
 DB 202 HSS-----YCVVAETIQPMLDRRSQR---SEERCVEI 230

R 14
 AAO17381
 ID AAO17381 standard; Protein; 231 AA.
 AC AAO17381;
 XX
 DT 08-AUG-2002 (first entry)
 XX
 DE Human cytokine receptor variant 2.
 XX
 KW Human; cytokine receptor; immune disease; psoriasis; cancer; infection;
 KW rheumatoid arthritis; multiple sclerosis; Crohn's disease;
 KW ulcerative colitis; transplant rejection; abortion; antipsoriatic;
 KW immunosuppressive; antirheumatic; antiarthritic; neuroprotective;
 KW antiinflammatory; antitumor; cytostatic; dermatological;
 KW chromosome 6q24.1-25.2; receptor.
 XX
 OS Homo sapiens.
 XX
 PN EPI191035-A2.
 XX
 PD 27-MAR-2002.
 XX
 PF 24-AUG-2002; 2001EP-0250307.
 XX
 PR 25-SEP-2000; 2000DE-1048626.
 PR 17-NOV-2000; 2000DE-1058907.
 PR 19-DEC-2000; 2000DE-1064906.
 XX
 PA (SCHD) SCHERING AG.
 XX
 PI Weiss B, Sabat R, Asadulliah K, Toshi L;
 XX
 DR WPI; 2002-332210/37.
 DR N-PSDB; AAL46000.
 XX
 PT New nucleic acid encoding soluble cytokine receptor, useful for
 PT diagnosis and treatment of e.g. immune disease, also related protein
 PT and antibodies
 XX
 PS Claim 6; Page 14; 21pp; German.
 XX
 CC The present invention provides the protein and coding sequences of 3
 CC variants of a human cytokine receptor. The sequences can be used in the
 CC diagnosis, prevention and treatment of immune diseases, including
 CC psoriasis, cancer, chronic/life-threatening infections, rheumatoid
 CC arthritis, multiple sclerosis, Crohn's disease, ulcerative colitis and
 CC transplant rejection and in reproductive medicine, e.g. for diagnosing
 CC abnormal immune reactions which cause abortions. The present sequence is
 CC variant 2 of the invention.
 XX
 SO Sequence 231 AA;

Query Match 13.8%; Score 156; DB 22; Length 231;
 Best Local Similarity 26.7%; Pred. No. 2.7e-08;
 Matches 58; Conservative 35; Mismatches 88; Indels 36; Gaps 11;

QY 11 PPSVFEAEFFHILHMT-IPNQSSTCYEVALLRGIESMNSISNC--SQTLSYDLTA 67
 DB 31 PQRVQOSNRFNHILOMOPGRALTGSSVYFQYKIQGRQKKNKEDCWTGDELSCDLTS 90
 QY 68 VTLDLHNSNGYRARVAVDGRSHSNMTVTNTRFS-----VDEVTLTGVSVNLIEHNGFI 121
 DB 91 ETSDI--GEPYGRVRAAASAGSYSEMSMT-PRFTPMWETKIDPPVNMITQV-----NGSL 142
 QY 122 LKGIQCP-----RPKMAPNDYTESISFHFREYEIAIRKVPGNFTTHKKVGHENFSL 174
 DB 143 LVTLAPNLPYRYOKKKNVSIEDYELLYRVF-IINNSLEKQKVEGAGHRAVEIEALTP 201
 QY 175 LTSGEVGEFCVQV--KPSVASRSNKGMSKECISL 208
 DB 202 HSS-----YCVVAETIQPMLDRRSQR---SEERCVEI 230

RESULT 15
 AAU80000
 ID AAU80000 standard; Protein; 231 AA.
 AC AAU80000;
 XX
 DT 15-JUL-2002 (first entry)
 XX
 DE Human IL-TIF/IL-22 binding protein #1.
 XX
 KW Human; soluble protein; interleukin-TIF/IL-22; IL-TIF/IL-22; IL-22BP;
 KW IL-TIF/IL-22 antagonist.
 XX
 OS Homo sapiens.
 XX
 PN WO200224912-A2.
 XX
 PD 28-MAR-2002.
 XX
 PF 21-SEP-2001; 2001WO-US29576.
 XX
 PR 22-SEP-2000; 2000US-234583P.
 PR 03-NOV-2000; 2000US-245495P.
 PR 31-JUL-2001; 2001US-0919162.
 XX
 PA (LUDW-) LUDWIG INST CANCER RES.
 XX
 PI Renauld J, Dumoutier L;
 XX
 DR WPI; 2002-383190/41.
 DR N-PSDB; ABK50076.
 XX
 PT Polynucleotide and polypeptide of soluble protein which binds to
 PT interleukin-TIF/IL-22 useful for inhibiting effect of IL-TIF/IL-22 on a
 PT cell
 XX
 PS Claim 14; Page 39; 42pp; English.
 XX
 CC The present invention relates to a new polynucleotide that encodes a
 CC soluble protein which binds to interleukin (IL)-TIF/IL-22 (also referred
 CC to as IL-22BP), where the complementary sequence of the invention
 CC hybridizes under stringent conditions to a nucleotide sequence of 2271
 CC or 2366 base pairs, as given in the specification. The molecules of the
 CC invention are useful for inhibiting (antagonizing) effect of IL-TIF/IL-22
 CC on a cell, for determining whether IL-TIF/IL-22 is present in a sample,
 CC for inhibiting binding of IL-TIF/IL-22 to a binding partner, preferably
 CC in vitro, and for obtaining an antibody molecule specific for the soluble
 CC binding protein of the invention, from a population or panel of antibody
 CC molecules of diverse binding specificity. The soluble protein is further
 CC useful in manufacture of a medicament for treating an IL-22 mediated
 CC disease and for assaying an agent, preferably an antibody or a peptide

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 13, 2003, 15:28:50 : Search time 11.6397 Seconds
(without alignments)
1742.692 Million cell updates/sec

Title: US-09-728-911-36

Sequence: 1 SDAGTELPSPSPVWFPEAF.....ASRSNKGWMSKECISLTRQ 211

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 283224 seqs, 96134422 residues

T number of hits satisfying chosen parameters: 283224

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: p1r1:*
2: p1r2:*
3: p1r3:*
4: p1r4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	1129	100.0	578	2	I56215	interleukin-10 receptor
2	602	53.3	575	2	A49667	interleukin-10 receptor
3	107.5	9.5	325	2	A47003	cytokine receptor
4	104.5	9.3	349	2	UC6311	interferon receptor
5	104.5	9.3	560	2	S27387	interferon receptor
6	96	8.5	6658	2	T11391	interferon alpha 1 protein
7	91	8.1	2410	1	J01948	genome polyprotein
8	90.5	8.0	802	2	C90326	hypothetical protein
9	88	7.8	1723	2	S58860	receptor DEC-205
10	88	7.8	2216	2	S78398	hypothetical protein
11	87.5	7.8	557	2	A32694	interleukin alpha1
12	87.5	7.8	936	2	F75622	hypothetical protein
13	86	7.6	337	2	I38500	interleukin gamma 1
14	84.5	7.6	2131	2	S01446	hypothetical protein
15	84.5	7.5	512	2	E64502	hypothetical protein
16	84.5	7.5	635	2	A45266	interleukin alpha1
17	84	7.4	590	2	A45283	interleukin alpha1
18	84	7.4	680	2	A42297	peptidyl-dipeptidase
19	84	7.4	680	2	AH0678	dipeptidyl carboxypeptidase
20	83	7.4	579	2	B45266	MP-L-K protein precursor
21	82.5	7.3	262	2	G69344	hypothetical protein
22	81.5	7.2	1235	1	DJBEAN	DNA-directed DNA polymerase
23	81.5	7.2	3014	1	JC5620	genome polyprotein
24	81	7.2	1694	2	H64106	IGA-specific metal
25	80.5	7.1	1702	2	A41859	IGA-specific metal
26	80.5	7.1	455	2	A55972	nicotinic acetylcholine receptor
27	80.5	7.1	455	2	S51116	cytochrome-c oxidase
28	80.5	7.1	481	2	E81050	hypothetical protein
29	80	7.1	307	2	C89836	hypothetical protein

30	80	7.1	375	2	T43049	hypothetical prote
31	80	7.1	602	2	A35564	prostaglandin-endo
32	80	7.1	774	2	T19244	hypothetical prote
33	79	7.0	981	2	S51604	receptor-like tyro
34	79	7.0	1240	1	DJBE21	DNA-directed DNA p
35	78.5	7.0	406	2	T31778	hypothetical prote
36	78	6.9	581	1	RGWVAV	trans-activating t
37	78	6.9	582	1	RGWVAV	trans-activating t
38	78	6.9	582	2	E72868	early gene transac
39	78	6.9	636	2	F72867	probable early gen
40	78	6.9	774	1	ORECPA	iron(III) diclrat
41	77.5	6.9	332	2	A49947	interferon gamma r
42	77.5	6.9	339	2	T40743	probable transcrip
43	77.5	6.9	447	2	A96639	protein TIF9.18 (i
44	77.5	6.9	733	2	T03117	glycoprotein H - a
45	77.5	6.9	1331	2	A48954	mannan endo-1,4-de

ALIGNMENTS

RESULT 1

156215
interleukin-10 receptor - human
C:Species: Homo sapiens (man)
C:Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 28-Jul-2000
C:Accession: I56215
R:Lin. Y.; Wei, S.H.; Ho, A.S.; de Maal Malefyt, R.; Moore, K.W.
U: Immunol. 152, 1821-1829, 1994
A:Title: Expression cloning and characterization of a human IL-10 receptor.
A:Reference number: I56215; MUID:94165477; PMID:8120391
A:Accession: I56215
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-578 <RES>
A:Cross-references: EMBL:U00672; NID:9482802; PIDN:AAA17896.1; PID:9482803
A:Gene: GDB:IL10R; HIL-10R
A:Genetics:
A:Cross-references: GDB:330958; OMIM:146933
A:Map position: 11q23.3-11q23.3
A:Superfamily: interleukin-10 receptor IL10R
C:Keywords: cytokine receptor

Query Match 100.0%; Score 1129; DB 2; Length 578;
Best Local Similarity 100.0%; Pred. No. 3.5e-97;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	SDAGTELPSPSPVWFPEAFHHILHTPIPNOSSTCYEVALLRYSWNSISCSQT	60
DB	19	SDAGTELPSPSPVWFPEAFHHILHTPIPNOSSTCYEVALLRYSWNSISCSQT	78
QY	61	LSYDLAVTLTDLVHNGYRVARVAVDGSRSNMTVTNTRFSVDEVTLLTVGSVNLRIHNGF	120
DB	79	LSYDLAVTLTDLVHNGYRVARVAVDGSRSNMTVTNTRFSVDEVTLLTVGSVNLRIHNGF	138
QY	121	ILGKIQLPRPKMAPNDYTESISREYEIAIRKYPGNFTTHKKVGHENFSLTSGEV	180
DB	139	ILGKIQLPRPKMAPNDYTESISREYEIAIRKYPGNFTTHKKVGHENFSLTSGEV	198
QY	181	GEPCVQKPSVASRSNKGWMSKECISLTRQ	211
DB	199	GEPCVQKPSVASRSNKGWMSKECISLTRQ	229

RESULT 2

A49667
interleukin-10 receptor - mouse
C:Species: Mus musculus (house mouse)
C:Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 28-Jul-2000
C:Accession: A49667
R:Ho, A.S.; Liu, Y.; Khan, T.A.; Heu, D.H.; Bazan, J.F.; Moore, K.W.
Proc. Natl. Acad. Sci. U.S.A. 90, 11267-11271, 1993
A:Title: A receptor for interleukin 10 is related to interferon receptors.

GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using SW model

Run on: January 13, 2003, 15:31:40 ; Search time 6.68662 Seconds
(without alignments)
612.211 Million cell updates/sec

Title: US-09-728-911-36

Perfect score: 11.9
Sequence: 1 SDHGTLPSPSPVWFEEAF.....ASRSKGMKXECISLTRQ 211

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 110974 seqs, 19401057 residues

Number of hits satisfying chosen parameters: 110974

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-Processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

1: Published Applications_AA.*
2: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

No.	Score	Query Match	Length	ID	Description
1	1129	100.0	211	US-09-728-911-36	Sequence 36, Appl
2	1129	100.0	578	US-09-912-672A-27	Sequence 27, Appl
3	156	13.8	210	US-09-728-911-13	Sequence 13, Appl
4	156	13.8	211	US-09-728-911-2	Sequence 2, Appl
5	156	13.8	231	US-09-949-197-6	Sequence 65, Appl
6	143	12.7	207	US-09-746-359A-65	Sequence 65, Appl
7	143	12.7	214	US-09-746-359A-63	Sequence 63, Appl
8	143	12.7	217	US-09-746-359A-55	Sequence 55, Appl
9	143	12.7	221	US-09-746-359A-12	Sequence 12, Appl
10	143	12.7	542	US-10-028-072-188	Sequence 188, App
11	143	12.7	542	US-10-052-586-398	Sequence 398, App
12	143	12.7	547	US-09-746-359A-54	Sequence 54, Appl
13	143	12.7	553	US-09-746-359A-11	Sequence 11, Appl
14	143	12.7	553	US-09-949-192-7	Sequence 7, Appl
15	143	12.7	559	US-09-746-359A-62	Sequence 62, Appl
16	143	12.7	571	US-09-746-359A-53	Sequence 53, Appl
17	143	12.7	594	US-09-746-359A-23	Sequence 23, Appl
18	139	12.3	217	US-09-746-359A-38	Sequence 38, Appl
19	139	12.3	514	US-09-746-359A-39	Sequence 39, Appl

20	139	12.3	546	US-09-746-359A-37	Sequence 37, Appl
21	125.5	11.1	308	US-09-912-672A-23	Sequence 23, Appl
22	122.5	10.9	196	US-09-746-359A-67	Sequence 67, Appl
23	122.5	10.9	201	US-09-912-672A-16	Sequence 16, Appl
24	122.5	10.9	201	US-09-746-359A-59	Sequence 59, Appl
25	122.5	10.9	203	US-09-746-359A-15	Sequence 15, Appl
26	122.5	10.9	282	US-09-912-672A-15	Sequence 15, Appl
27	122.5	10.9	307	US-09-746-359A-58	Sequence 58, Appl
28	122.5	10.9	311	US-09-978-295A-352	Sequence 352, App
29	122.5	10.9	311	US-09-992-598-183	Sequence 183, App
30	122.5	10.9	311	US-09-912-672A-12	Sequence 12, Appl
31	122.5	10.9	311	US-09-978-697-352	Sequence 352, App
32	122.5	10.9	311	US-09-978-192A-352	Sequence 352, App
33	122.5	10.9	311	US-09-989-293A-183	Sequence 183, App
34	122.5	10.9	311	US-09-989-735-183	Sequence 183, App
35	122.5	10.9	311	US-09-990-444-183	Sequence 183, App
36	122.5	10.9	311	US-09-990-832A-352	Sequence 352, App
37	122.5	10.9	311	US-09-989-730-183	Sequence 183, App
38	122.5	10.9	311	US-09-990-436-183	Sequence 183, App
39	122.5	10.9	311	US-09-991-181-183	Sequence 183, App
40	122.5	10.9	311	US-09-993-687-183	Sequence 183, App
41	122.5	10.9	311	US-09-978-189-352	Sequence 352, App
42	122.5	10.9	311	US-09-989-734-183	Sequence 183, App
43	122.5	10.9	311	US-10-028-072-32	Sequence 32, Appl
44	122.5	10.9	311	US-09-746-359A-34	Sequence 34, Appl
45	122.5	10.9	311	US-09-989-722-183	Sequence 183, App

ALIGNMENTS

```

RESULT 1
US-09-728-911-36
; Sequence 36, Application US/09728911
; Patent No. US002001269A1
; GENERAL INFORMATION:
; APPLICANT: Presnell, Scott R.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Kindsvoegel, Wayne
; APPLICANT: Chen, Zhi
; TITLE OF INVENTION: Human Cytokine Receptor
; FILE REFERENCE: 99-93
; CURRENT APPLICATION NUMBER: US/09/728, 911
; PRIOR FILING DATE: 2000-12-01
; PRIOR APPLICATION NUMBER: US 60/169, 049
; PRIOR FILING DATE: 1999-12-03
; PRIOR APPLICATION NUMBER: US 60/232, 219
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: US 60/244, 610
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 36
; LENGTH: 211
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-728-911-36
Query Match      100.0%; Score 1129; DB 10; Length 211;
Best Local Similarity 100.0%; Pred. No. 2.4e-110;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1 SDHGTLPSPSPVWFEEAFHHILHWTPINQSESTCYEVALRYGIESMNSISNCSQT 60
DB      1 SDHGTLPSPSPVWFEEAFHHILHWTPINQSESTCYEVALRYGIESMNSISNCSQT 60
QY      61 LSYDITAVTLDLHNSNGRAVRAYVDGSRHSNMTVTNTRFSVDVTLTVGSVNIENNGF 120
DB      61 LSYDITAVTLDLHNSNGRAVRAYVDGSRHSNMTVTNTRFSVDVTLTVGSVNIENNGF 120
QY      121 ILGKIQLRPKAPANDYESIFSHFREYEAIRKVGCFEFTKKKXVHEVFSLLTSGEV 180
DB      121 ILGKIQLRPKAPANDYESIFSHFREYEAIRKVGCFEFTKKKXVHEVFSLLTSGEV 180

```

QY 181 GBFCVQKPSVASRSNKGWMSKEECISLTRQ 211
Db 181 GBFCVQKPSVASRSNKGWMSKEECISLTRQ 211

RESULT 2

US-09-912-672A-27
; Sequence 27, Application US/09912672A
; Patent No. US2002016469A1
; GENERAL INFORMATION:
; APPLICANT: Busfield, Samantha J.
; TITLE OF INVENTION: CLASS II CYTOKINE RECEPTOR-LIKE PROTEINS
; TITLE OF INVENTION: AND NUCLEIC ACIDS ENCODING THEM
; FILE REFERENCE: 07334-184001
; CURRENT APPLICATION NUMBER: US/09/912,672A
; PRIOR FILING DATE: 2001-07-23
; PRIOR APPLICATION NUMBER: 09/475,541
; PRIOR FILING DATE: 1999-12-30
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 27
; LENGTH: 578
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-912-672A-27

Query Match 100.0%; Score 1129; DB 9; Length 578;
Best Local Similarity 100.0%; Pred. No. 9.7e-110;
Matches 211; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SDAHGTLPSPSVWFEEAFHHILHWTPIPNQSESTCYEVALRYGIESWNSISNCSQT 60
Db 19 SDAHGTLPSPSVWFEEAFHHILHWTPIPNQSESTCYEVALRYGIESWNSISNCSQT 78
QY 61 LSYDLTAVTLDLYHNGYRVARVDGSRHSNWTNTNTRFSVDEVTLVGSVNLEIHNGF 120
Db 79 LSYDLTAVTLDLYHNGYRVARVDGSRHSNWTNTNTRFSVDEVTLVGSVNLEIHNGF 138
QY 121 ILGKIQLPRKMAPANDTYESIFSHFREYEAIRKVPNGNFTFTHKKVKHNFSLTSGEV 180
Db 139 ILGKIQLPRKMAPANDTYESIFSHFREYEAIRKVPNGNFTFTHKKVKHNFSLTSGEV 198
QY 181 GBFCVQKPSVASRSNKGWMSKEECISLTRQ 211
Db 199 GBFCVQKPSVASRSNKGWMSKEECISLTRQ 229

RESULT 3

US-09-728-911-13
; Sequence 13, Application US/09728911
; Patent No. US2002012669A1
; GENERAL INFORMATION:
; APPLICANT: Presnell, Scott R.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Kindsvogel, Wayne
; APPLICANT: Chen, Zhi
; TITLE OF INVENTION: Human Cytokine Receptor
; FILE REFERENCE: 99-93
; CURRENT APPLICATION NUMBER: US/09/728,911
; CURRENT FILING DATE: 2000-12-01
; PRIOR APPLICATION NUMBER: US 60/169,049
; PRIOR FILING DATE: 1999-12-03
; PRIOR APPLICATION NUMBER: US 60/232,219
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: US 60/244,610
; PRIOR FILING DATE: 2000-10-31
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 13
; LENGTH: 210
; TYPE: PRT
; ORGANISM: Homo sapiens

US-09-728-911-13

Query Match 13.8%; Score 156; DB 10; Length 210;
Best Local Similarity 26.7%; Pred. No. 6.9e-09;
Matches 58; Conservative 35; Mismatches 88; Indels 36; Gaps 11;

QY 11 PPSVWFEEAFHHILHWTPIPNQSESTCYEVALRYGIESWNSISNCSQTLSYDLTA 67
Db 10 PORVQFSRNFHILQWQGRALTGNSSVYFQYKIYQORQMKNKEDCWGTQELSCLDLS 69
QY 68 VTLDLYHNGYRVARVDGSRHSNWTNTNTRFSVDEVTLVGSVNLEIHNGFI 121
Db 70 ETSDI--QEPYIGRVRAASAGSYSEWSMT-PRFTPWETKIDPPVNNITQV-----NGSL 121
QY 122 LGKIQLP-----RPKMAPANDTYESIFSHFREYEAIRKVPNGNFTFTHKKVKHNFSL 174
Db 122 LVILHAPNLPYRYQEKVNSIEDYVELLYRVF-IINNSLEKEQKVYEGAHRAVEIEALTTP 180
QY 175 LTSGEVGEFCVQV---KPSVASRSNKGWMSKEECISL 208
Db 181 HSS-----YCVVAEIIYQPMIDRRSQR---SEERCVEI 209

RESULT 4

US-09-728-911-2
; Sequence 2, Application US/09728911
; Patent No. US2002012669A1
; GENERAL INFORMATION:
; APPLICANT: Presnell, Scott R.
; APPLICANT: Xu, Wenfeng
; APPLICANT: Kindsvogel, Wayne
; APPLICANT: Chen, Zhi
; TITLE OF INVENTION: Human Cytokine Receptor
; FILE REFERENCE: 99-93
; CURRENT APPLICATION NUMBER: US/09/728,911
; CURRENT FILING DATE: 2000-12-01
; PRIOR APPLICATION NUMBER: US 60/169,049
; PRIOR FILING DATE: 1999-12-03
; PRIOR APPLICATION NUMBER: US 60/232,219
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: US 60/244,610
; PRIOR FILING DATE: 2000-10-31
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 231
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-728-911-2

Query Match 13.8%; Score 156; DB 10; Length 231;
Best Local Similarity 26.7%; Pred. No. 7.8e-09;
Matches 58; Conservative 35; Mismatches 88; Indels 36; Gaps 11;

QY 11 PPSVWFEEAFHHILHWTPIPNQSESTCYEVALRYGIESWNSISNCSQTLSYDLTA 67
Db 31 PORVQFSRNFHILQWQGRALTGNSSVYFQYKIYQORQMKNKEDCWGTQELSCLDLS 90
QY 68 VTLDLYHNGYRVARVDGSRHSNWTNTNTRFSVDEVTLVGSVNLEIHNGFI 121
Db 91 ETSDI--QEPYIGRVRAASAGSYSEWSMT-PRFTPWETKIDPPVNNITQV-----NGSL 142
QY 122 LGKIQLP-----RPKMAPANDTYESIFSHFREYEAIRKVPNGNFTFTHKKVKHNFSL 174
Db 143 LVILHAPNLPYRYQEKVNSIEDYVELLYRVF-IINNSLEKEQKVYEGAHRAVEIEALTTP 201
QY 175 LTSGEVGEFCVQV---KPSVASRSNKGWMSKEECISL 208
Db 202 HSS-----YCVVAEIIYQPMIDRRSQR---SEERCVEI 230

RESULT 5

US-09-949-192-6